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Corporate coalitions and policymaking in the European Union: How and why 
British American Tobacco promoted ‘Better Regulation’ 
 
Abstract: 
Over the past fifteen years, an inter-connected set of regulatory reforms, known as Better 
Regulation, has been adopted across Europe, marking a significant shift in the way European 
Union (EU) policies are developed.  There has been little exploration of the origins of these 
reforms, which include mandatory ex-ante impact assessment.  Drawing on documentary and 
interview data, this paper discusses how and why large corporations, notably British 
American Tobacco (BAT), worked to influence and promote these reforms.  Our analysis 
highlights: (i) how policy entrepreneurs with sufficient resources (such as large corporations) 
can shape the membership and direction of advocacy coalitions; (ii) the extent to which ‘think 
tanks’ may be prepared to lobby on behalf of commercial clients; and (iii) why regulated 
industries (including tobacco) may favour the use of ‘evidence-tools’, such as impact 
assessments, in policymaking. We argue a key aspect of BAT’s ability to shape regulatory 
reform involved the deliberate construction of a vaguely defined idea that could be 
strategically adapted to appeal to diverse constituencies.  We discuss the theoretical 
implications of this finding for the ‘Advocacy Coalition Framework’, as well as the practical 
implications of the findings for efforts to promote ‘transparency’ and public health in the EU.    
 
 
Introduction: 
Since the early 1990s, the concept of ‘Better Regulation’ has been increasingly used to 
describe a rolling programme of regulatory reform taking place at both European Union (EU) 
(Allio, 2007; Commission of the European Communities, 2009) and European Member State 
level (Radaelli, 2005; Radaelli and Meuwese, 2010; Department for Business, Enterprise & 
Regulatory Reform, 2007; Better Regulation Task Force, 2005; Department of the Taoiseach, 
2004).  Despite shifting interpretations of the term (Radaelli, 2007a), it is possible to identify 
three core themes within Better Regulation discourses.  First, the term is associated with an 
imperative to improve the quality of regulatory decision-making, notably through the 
increased use of evidence (Department for Business, Enterprise & Regulatory Reform, 2007; 
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Department of the Taoiseach, 2004).  Second, there is often a particular focus on the impacts 
of regulation on business competitiveness (Commission of the European Communities, 2005; 
Department of the Taoiseach, 2004; EU Presidencies, 2004). Regulatory Impact Assessment (a 
form of Business Impact Assessment) is frequently advocated as a means of addressing these 
first two strands (Radaelli, 2007b; Carroll, 2010).  Third, the principles of Better Regulation are 
often framed as a means of achieving a ‘simplified’ regulatory environment (Department for 
Business, Enterprise & Regulatory Reform, 2007; Commission of the European Communities, 
2002; Department of the Taoiseach, 2004), in which ‘self-regulation’ and ‘co-regulation’ are 
promoted as alternatives to traditional legislation (Commission of the European 
Communities, 2002; Department of the Taoiseach, 2004; EU Presidencies, 2004).  Finally, 
Better Regulation is associated with a commitment to transparency and dialogue (Better 
Regulation Task Force, 2005; Commission of the European Communities, 2002; Department 
of the Taoiseach, 2004; EU Presidencies, 2004).  
 
The roots of Better Regulation in the EU date back to the 1980s, when European Community 
policymakers formally began to link a reduction of regulatory costs to business 
competitiveness and economic growth (e.g. Commission of the European Communities, 
1986a, 1986b).  The UK was the first EU Member State to formally adopt the term, using it 
widely in documents from 1997 onwards (e.g. Cabinet Office, 1997; Department for Business, 
Enterprise & Regulatory Reform, 2007).  However, it was not until 2000 that a comprehensive 
and politically visible Better Regulation agenda was conceived at the EU level (Allio, 2007). To 
date, there have been few empirical analyses of the origins of Better Regulation in the EU.  
Radaelli (2007b) claims it emerged from concerns amongst some Member States (particularly 
the UK) about the quality and quantity of EU regulations and constituted an attempt by these 
member states to control the European Commission; Renda (2006, p.43) attributes its 
development to concerns about ‘regulatory creep’ and ‘disappointing economic performance’; 
Allio (2007; see Table 2) traces its origins to a growing concern amongst European 
policymakers that foreign direct investment might shift to jurisdictions with lower regulatory 
costs; and Löfstedt (2006) points to the influence of US political and economic institutions.   
 
In press: Journal of Health Politics, Policy and Law 
  
4 
Of the various innovations to emerge from the Better Regulation agenda, the mandatory 
requirement for EU policymakers to undertake impact assessments (IAs) for virtually all policy 
decisions is perhaps the most significant and is widely interpreted as constituting an 
important shift in regulatory policymaking (Allio, 2007; Radaelli & Meuwese, 2008; Radaelli & 
Meuwese, 2010).  In general terms, IA is a means of assessing the impacts of a potential (or 
existing) policy (Curtis, 2008; Mindell et al, 2004; Radaelli, 2008) but specific definitions vary 
(e.g. Löfstedt, 2004; Parry and Kemm, 2005; Radaelli, 2005; 2007b) and IA tools differ across 
policy contexts (Radaelli, 2005).  A multitude of IA types now exist, including Business IAs, 
Health IAs and Environmental IAs.  When applied to the regulation of substances which pose 
threats to human health and/or the environment, such as tobacco, alcohol or toxic chemicals, 
IA provides a framework for making decisions about whether and how to limit the resulting 
health and/or environmental damage (Michaelson, 1996).  The first stage of IA usually 
involves some form of risk assessment in order to assess whether the risks posed by a 
particular hazard are great enough to warrant regulation (Curtis, 2008; Kopp et al, 1997; 
Majone, 2003).  If policy intervention is deemed necessary, the likely impacts of each policy 
option may then be assessed in a process similar to cost-benefit analysis (CBA), which 
involves assessing policy options by quantifying the value of positive and negative impacts in 
quantitative (usually monetary) terms.  The theory underlying CBA is that this process helps 
‘effective social decision making through efficient allocation of society’s resources when 
markets fail’ (Boardman et al., 2006, p23).   
 
IA and CBA are widely regarded as useful decision-making aids and their use within 
policymaking is supported by business organisations (e.g. BusinessEurope, undated) and 
academics (e.g. Hahn and Litan, 1997; Kopp et al, 1997; Sunstein, 2002).  The use of particular 
forms of IA within policymaking, notably Health IAs and Environmental IAs, has also been 
promoted by researchers and advocates concerned with public health and environmental 
debates (e.g. British Medical Association, 1999; McCarthy et al, 2002; Mindell and Joffe, 2003; 
Wright et al, 2005).  There are, however, a number of critiques of IA and CBA, some of which 
raise questions about their political neutrality (e.g. Chichilnisky, 1997; Driesen, 2006; Kelman, 
1981; Michaelson, 1996; Sen, 2000).  A key concern is the difficulty in accurately predicting 
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ex-ante impacts and the risk that IA may provide policymakers with a misleading sense of 
certainty about the consequences of particular decisions (e.g. Tennøy et al., 2006).  These 
risks are perhaps greatest where IAs attempt to quantify relative costs and benefits in 
monetary terms and where non-market goods, such as health and environmental impacts, are 
involved (Michaelson, 1996; Sen, 2000). Quantification in these circumstances can obscure 
and oversimplify what are, in effect, highly complex and contested issues involving moral 
judgments and decisions about competing political priorities (Kelman, 1981; O'Connell and 
Hurley, 1997; Miller and Patassini, 2005).  Another concern that has been raised is that the 
time-consuming nature of producing IAs can lead to significant legislative delays (Driesen, 
2006; Krieger et al, 2003). Finally, IAs can increase policymakers’ informational dependency 
on resource-rich stakeholders with commercial interests in socially suboptimal policy 
outcomes (Smith et al., 2010). Given the opportunities that these complexities open up for 
different interests, it seems important to explore which actors worked to promote Better 
Regulation and the use of IA within the EU, how they tried to shape these agendas and what 
they hoped to achieve as a result. 
 
The following account begins with a brief explanation of the methods employed and the 
theoretical approach, before explaining the particular interest of British American Tobacco 
(BAT) in Better Regulation and IA within Europe.  After this, the paper presents a largely 
chronological account of the findings, explaining what kinds of policy change BAT managers 
hoped to achieve, why they believed these changes would benefit the company, and how 
they worked with others, notably a Brussels-based think tank called the European Policy 
Centre (EPC - see Table 1), to try to achieve these changes.  Specifically, we explore whether 
the vaguely defined nature of ‘Better Regulation’ reflects BAT’s strategic approach to 
promoting regulatory reform in the EU.  The concluding discussion considers the 
appropriateness of IA as a tool for practical decision-making, the limits of current 
‘transparency’ initiatives in the EU and the theoretical implications of our findings for Sabatier 
and Jenkins-Smith’s (1999) widely-employed ‘Advocacy Coalition Framework’. 
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Methods 
This paper uses tobacco industry documents, released through litigation, other publicly 
available documents and interviews with EU officials and lobbyists, to explore why large 
corporations were interested in these reforms, how they attempted to shape the Better 
Regulation agenda and, in particular, to embed CBA and risk assessment into the EU’s 
approach to IA (i.e. what the chosen strategies and tactics involved).  The tobacco industry 
documents are available following litigation in the US which required tobacco companies to 
make many of their internal documents public. There are currently over 80 million documents 
and they can be searched using optical character recognition via the online Legacy library 
(http://www.legacy-library.ucsf.edu). 
 
We undertook iterative searches of these documents between mid-April and September 
2008.  In total, approximately 6,800 documents were reviewed. Of these, 714 were identified 
as relevant to the story of BR in Europe on the basis that they included references to 
European regulation processes, BAT’s specific regulatory objectives (e.g. IA, CBA and risk 
assessment) or key organisations or individuals. The remaining 6,086 documents either 
appeared to have no relevance to BR, IA, risk assessment or they were duplicates of 
documents we did include.  The 714 relevant documents were imported to an EndNote 
library, from where they were re-read (in date order), interpreted and thematically coded by 
an experienced, qualitative researcher.  The coding process involved highlighting specific 
components of BAT’s interest in EU regulatory reform (i.e. what BAT hoped to achieve with 
regard to IA, CBA, risk assessment, stakeholder consultation, transparency, etc), key 
individuals and organisations that were involved in the process, mechanisms and strategies 
employed to shape the agenda and indicators and assessments of progress.  Documents were 
also coded in terms of document type (e.g. whether the document was a letter, an email, an 
internal report, etc) and authorship (where this was discernable).  This article draws on a 
section of these documents to present the key findings from this research. The interpretation 
of all documents was checked by at least one other researcher. 
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Although the tobacco industry documents provide valuable insights into the internal 
strategies of some of the world’s largest tobacco companies, it is important to recognise that 
this resource does not represent the entire backlog of internal company documents  
(MacKenzie and Collin and Lee, 2003).  Rather, the documents were released as a result of a 
process of discovery during litigation.  Consequently, these documents are often fragmentary 
and provide only a partial picture of an organisation’s activities (MacKenzie and Collin and 
Lee, 2003).  In addition, far fewer documents are available from 2000 onwards, which limits 
the relevance of the documents for understanding more recent developments. For all these 
reasons, we contextualised our analysis of the internal tobacco company documents using a 
range of other sources, including interviews with relevant individuals and electronic searches 
of other databases and online sources (e.g. of the organisations that had been mentioned in 
the internal tobacco documents and interviews). 
 
In total, we approached 16 individuals for an interview on the basis that they had been 
involved in policy decisions and debates relating to BR and IA in the EU since 1997 or that 
they were specifically mentioned within BAT’s documents relating to BR (see Table 2).  The 
exceptions to this were Bruce Ballantine (Table 2), who died before we commenced this 
research and individuals who still worked for BAT (see below).  All but three of the individuals 
we approached agreed to be interviewed.  Of these 13, the following three interviewees 
agreed to be named: Charles Miller (who led the Fair Regulation Campaign), Stanley Crossick 
(who co-founded the EPC and worked directly with BAT on the Better Regulation agenda) and 
David Byrne (Commissioner for Health and Consumer Protection 1999–2004).  The other ten 
interviewees included three members of European Commission staff who were involved in 
the development and implementation of Better Regulation and/or IA, one member of 
European Commission staff based in DG SANCO (the Directorate General responsible for 
health and consumer protection), three heads of voluntary organisations working to promote 
public health and environmental issues in the EU, one head of an EU based think tank (other 
than EPC), one senior member of a major Brussels based consultancy firm and one UK civil 
servant who held responsibility for Better Regulation/IA issues in the UK government.  Tables 
1 and 2 provide an overview of the key individuals and organisations mentioned in this article. 
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The interviews were transcribed and analysed alongside the documentary data and although, 
between them, the interviewees held contrasting views about BR, IA and the tobacco 
industry, the information interviewees provided was largely consistent with the information 
garnered through our analysis of the internal tobacco documents, supporting our 
interpretation.  Several of our interviewees were surprised to learn that BAT had been 
involved in efforts to promote and shape Better Regulation and two (policy-based) 
interviewees said they believed BAT had not been involved but they provided no evidence to 
substantiate this belief or to counter the findings presented here. This article draws on a 
selection of our various data sources to present the key findings; the lead author (KS) led the 
analysis but the interpretation of all sources employed in this article was checked by at least 
one other author.  Minor revisions to the wording of some sections was made as a result. 
 
Our analysis is undertaken from a public health perspective and it should be acknowledged 
that, by employing internal tobacco industry documents as one of our main sources, our 
findings inevitably say more about British American Tobacco’s interests in regulatory reform 
than they do about the interests of other organisations (e.g. the other companies involved).   
In addition, while our selection of interviewees was based on a thorough documentary 
analysis, the sample might have excluded some important informants who were not 
identified in the documents we identified.  Finally, although we interviewed individuals who 
had undertaken work on behalf of BAT, we chose not to approach current BAT employees for 
interview because we considered the internal documents likely to provide a more accurate 
representation of BAT thinking at the time of the reforms and not subject to social desirability 
or recall bias (as contemporaneous interviews with BAT staff may have been). 
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Theoretical approach: Employing the ‘Advocacy Coalition Framework’ 
The case study builds on a wealth of existing research concerning corporate lobbying and 
policy influence in the EU (e.g. Bouwen, 2002; Coen and Richardson, 2009; Woll, 2007) which 
charts the ‘growing political sophistication of public and private interests in a complex multi-
level venue policy environment’ (Coen, 2007: p333).  It provides a basis for assessing the 
utility of one of the most popular theories of policy change, Sabatier and Jenkins-Smith’s 
(1999) Advocacy Coalition Framework (ACF). The ACF suggests that diverse groups of actors 
form relatively stable coalitions around core ideas (relating to values and beliefs about 
causation) within particular ‘policy sub-systems’. The Framework posits that, once a particular 
coalition comes to dominate a policy subsystem, policy change is likely to be limited but that 
significant policy change can occur when a particular coalition’s ideas are perceived to be so 
successful that some actors switch between competing coalitions, shifting the balance of 
power in relation to the ‘core ideas’ driving policy.  
 
The policy sub-system with which this paper is concerned is the regulation of business 
interests in order to protect social (particularly health) or environmental interests, a sub-
system in which two distinct coalitions were identifiable in the 1980s and early 1990s 
(Farquharson, 2003; Smith, 2013a).  One consisted of actors concerned with the health and 
environmental harms caused by some economic activity (largely made up of some civil society 
and non-governmental organisations, academics, politicians and professional medical 
groups).  To use the terminology of ACF, a policy core belief held by this group was that 
regulatory intervention provides a crucial means of preventing harms to the environment and 
public health.  The second, competing coalition consisted of actors concerned with the ability 
of businesses to operate freely and competitively (this group largely consisted of businesses, 
business organisations and think tanks, as well as some academics and politicians).  A policy 
core belief held by this group was that businesses should be able to operate as freely as 
possible in the EU (which was conceived of as a largely economic project) and that EU 
regulations should only be implemented to address market failures (and only where 
regulations at the Member State level were demonstrably insufficient).  It seems likely that 
policymakers, both at EU and Member State level, were (and remain) split between these two 
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coalitions, with many viewing themselves as arbitrators between the two (this was indeed the 
way many of our interviewees characterised the situation).  Our data indicate that, by the 
mid-1990s, BAT managers were becoming increasingly concerned that policymakers in the EU 
were becoming sympathetic to the first group’s views.  Regulatory reform appears to have 
been conceived of by BAT managers as a means of shifting the balance of power back in 
favour of business and economic priorities.  Combined with the wide range of actors involved 
and the time period of more than a decade, all this suggests that the ACF may offer a valuable 
hermeneutic device for making sense of recent regulatory change in the EU. However, as the 
concluding section outlines, our findings also challenge the ACF by drawing attention to the 
importance of studying the characteristics of the particular ideas that are developed and 
promoted by coalitions actors, alongside the networks of actors involved. 
 
The particular focus of this paper on the tobacco industry and its involvement in regulatory 
change is important in light of the fact tobacco remains the leading cause of avoidable 
premature mortality in Europe (Mackenbach et al, 2013).   It is estimated, based on Eurostat 
data, that in 2009 about 9.9 million years of life were lost due to smoking-attributable 
premature mortality and that the total cost to the 27 EU member states was about €544 
billion (Jarvis, 2012).  The tobacco industry has been framed as a ‘vector’ of this epidemic of 
tobacco-related morbidity and mortality (LeGresley, 1999) and has, largely as a consequence 
of this, become increasingly excluded from formal health policy discussions (WHO, 2003). 
Despite this, tobacco-related policy developments in the EU remain highly controversial and 
deeply politicised, as the recent resignation of EU Health Commissioner, John Dalli, in the 
context of claims he knew of efforts to bribe a tobacco company, illustrates1 (Watson, 2012).  
The findings of this paper, which demonstrate the sophisticated and complex nature of 
                                                 
1 EU Health Commissioner, John Dalli, resigned in October 2012, following pressure from Commission President 
José Manuel Barosso, which related to accusations that Dalli had been aware that a Maltese businessman with 
whom he was acquainted had tried to bribe tobacco company Swedish Match (which manufactures an oral 
tobacco known as ‘snus’) for €60 million to secure a removal of the European ban on snus (see Watson, 2012 for 
more details). Within 36 hours of Dalli’s resignation, the offices of the three main anti-smoking NGOs based in 
Brussels had been burgled (Watson, 2012). One consequence of all this was to delay the passage of a 
controversial EU tobacco policy, the revised Tobacco Products Directive (Watson, 2012). 
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tobacco industry efforts to influence policy, are therefore also of interest from a public health 
perspective. 
 
We note, at the outset, that the tobacco industry documents drawn upon often use the terms 
‘IA’ and ‘CBA’ interchangeably, reflecting the fact that the version of IA being promoted by 
tobacco interests involved an economic framework resembling CBA.  For the most part, this 
paper focuses on IA.  However, the term CBA is employed where appropriate when we are 
quoting directly from tobacco industry documents.  By outlining what corporations involved 
in regulatory reform hoped to achieve, the paper provides an important addition to recent 
accounts of the European emergence of Better Regulation and IA which focus on the role of 
the Commission and particular Member States (e.g. Radaelli & Meuwese, 2010; Radaelli, 
2007b; Allio, 2007). 
 
British American Tobacco (BAT) and Better Regulation  
(i) Contextualising BAT’s interest in Better Regulation and IA  
The emergence of neo-liberalism as a governing political philosophy in many EU member 
states in the 1980s and 1990s (van Apeldoorn, 2003) coincided with a renewed emphasis on 
deregulation as a means of improving business competitiveness and market efficiency 
(Department of Trade and Industry, 1985, 1988; Commission of the European Communities, 
1993).  However, in contrast to other industries, which are typically thought to have enjoyed 
a renaissance in their policy influence during this period (Farnsworth, 2004; Farnsworth & 
Holden, 2006), the tobacco industry had begun to experience a significant decline in its 
credibility and political authority (Sanders, 1997), with many of its traditional techniques of 
policy influence coming under increasing scrutiny from both public health advocates and 
public officials (Fooks et al., 2013). 
 
At the same time, the tobacco industry was becoming increasingly concerned about the 
extent of tobacco control legislation emanating from the EU (Gilmore and McKee, 2004) and 
broader corporate concern was growing around the use (and potential use) of the 
‘Precautionary Principle’ in the EU (BAT, 2000a; EPC, 1998).  This principle applies to 
In press: Journal of Health Politics, Policy and Law 
  
4 
circumstances in which there are reasonable grounds to believe that a given hazard would, if 
it occurred, result in severe or irreversible damage to public health or the environment, and it 
calls on policymakers to intervene to prevent such hazards, even when there is no clear 
scientific consensus about the likelihood of the hazard occurring (Commission of the 
European Communities, 2000).  Some commentators argue that the Precautionary Principle is 
inconsistent with scientific approaches to policymaking and does not sufficiently take account 
of economic efficiency (Allio et al., 2005; EPC Risk Forum; 2005).  Indeed, as Löfstedt (2002) 
notes, many business interests came to perceive the Precautionary Principle ‘as a tool for the 
more radical environment and health advocates’.  
 
It is in this context that BAT began to consider ways of increasing its influence over EU policy 
by promoting the need for a form of structured risk assessment to be embedded within the 
European legislative process (BAT, 1995; Chalfen, 1996a, 1996b, 1996c).  It might appear 
paradoxical that risk assessment could be promoted by a company whose products were well 
known to pose serious risks to human health (Royal College of Physicians, 1962; National 
Cancer Institute, 1993).  Indeed, BAT was warned by one of its political consultants, Charles 
Barker (see Table 1), that such an approach might work against the company’s interests 
(MacKenzie-Reid, 1995).  However, having closely monitored Philip Morris’s use of risk 
assessment to undermine proposed restrictions on environmental tobacco smoke in the US 
(Hirschhorn & Bialous, 2001; Ong & Glantz, 2001; Muggli et al., 2004), senior BAT managers 
took the view that a policy requirement for a particular form of risk assessment could help 
the company defeat efforts to introduce policies restricting smoking (BAT, 1995, undated-a).  
This would be achieved through promoting a set of rules for assessing epidemiological data, 
within risk assessment, that would place the bar for what constitutes ‘unacceptable risk’ 
above that posed by environmental tobacco smoke (see Bero, 2012). 
 
(ii) Building a coalition of support around a malleable concept 
BAT was aware that a proposal for risk assessment guidelines promoted solely by a large 
tobacco company was unlikely to be received favourably (Mackenzie-Reid, 1995).  
Consequently, the strategies BAT employed to promote this issue were collaborative and 
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indirect, obscuring specific, tobacco-related objectives.  Hence, BAT was advised by the 
consultancy company, Charles Barker to construct a supportive coalition of interests, initially 
focusing on recruiting other businesses with potentially overlapping interests in risk 
assessment: 
 
'As a first step, BATCo should seek to identify industries that would benefit from risk 
assessment guidelines […]. The pharmaceutical industry would be a clear contender 
since research on the veracity of drugs prior to medicinal approval may well be linked 
to assessments which overstate the degree of danger. Similar considerations apply to 
the oil and chemical industries, especially in relation to the assessment of 
environmental dangers. All industry would however benefit from clearer assessment 
guidelines if that resulted in a reduction in compliance costs associated with health & 
safety legislation. There would be clear benefits in persuading the CBI [Confederation 
of British Industry] to launch an initiative on risk assessment, especially since they have 
two appointees on the Health & Safety Commission.' (MacKenzie-Reid, 1995) 
 
Reflecting this advice, BAT solicitor, Stuart Chalfen, subsequently wrote to other companies 
involved in manufacturing and marketing regulated products (Chalfen, 1996b, 1996d, 1996c, 
1997) although not (as far as it is possible to tell) to other tobacco companies.  A meeting 
involving BAT staff and representatives from some of the companies Chalfen approached 
(including Elf Aquitaine, Imperial Chemical Industries (ICI) and Zeneca) was subsequently held 
in Brussels in January 1997.  The minutes of this meeting note that a key part of the proposed 
strategy for achieving regulatory reform would involve generating ‘a large reservoir of 
informed and favourable opinion towards the project across the EU which [could] be activated 
at short notice at the appropriate time' (Anonymous, 1997a).  In other words, the aim was to 
create the sense amongst policymakers that there was a widely-held consensus in support of 
these regulatory reforms within the business community.  As we describe later on, the 
business interests involved were subsequently expanded, including via a separate, UK-based 
group known as the Fair Regulation Campaign (see Figure 1; Table 1 and p 19, below).   
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<Figure 1 here> 
  
The consultancy firm Charles Barker also advised BAT to use a ‘front group’ to expedite the 
campaign to promote regulatory reform (MacKenzie-Reid, 1995), noting that public 
knowledge of tobacco industry involvement could seriously undermine the campaign’s 
credibility (Honour, 1996). After briefly considering the idea of conscripting a centre left 
institute or think tank to ‘confound the critics’, (Fitzsimons, 1995), BAT managers turned to 
the EPC, a leading Brussels-based think tank (Sherrington, 2000; Table 1) with ‘a broad 
political profile across a number of issue domains’ (Coen, 1998, p.78).  The EPC received 
funding from the European Commission (EPC, 2009), which bestowed it with something of an 
‘insider’ status (Broscheid & Coen, 2003).  These features made the EPC an excellent platform 
from which to present the regulatory reforms as credible and non-partisan to policymakers 
and journalists.  
 
BAT was initially advised by both UK-based consultancy firm the Public Policy Unit (Table 1) 
and Brussels-based lobbyist Stanley Crossick (Table 2) that the European Commission was not 
interested in developing risk assessment in the way BAT envisioned2 (Gretton, 1996b; 
Crossick, 1996b). In February 1996, the legal firm Covington & Burling (see Table 1) suggested 
that an alternative way forward might be to situate any discussion of risk assessment within 
the context of the European Commission’s existing commitment to undertaking Business IAs 
(Covington & Burling, 1996).  Known as fiches d’impact, these basic Business IAs had been 
mandated in the EU since 1986 (Commission of the European Communities, 1986a) and 
focused on assessing the potential impacts of EU legislative proposals on small and medium-
sized enterprises (SMEs) (Commission of the European Communities, 1986b).  In practice, 
their use was erratic and, when conducted, seemed to involve only limited information (Froud 
et al. 1998).  However, Covington & Burling advised BAT that the Commission's priorities for 
1996 included the implementation of revised guidelines for fiches d’impact and suggested 
                                                 
2 As described elsewhere (Bero, in press) the Commission had actually already begun employing risk assessments 
in some policy sectors and, on that basis, we presume the advice that BAT received which suggested the 
Commission was not interested in risk assessment meant that the Commission was not interested in the kind of 
mandatory (cross-sectoral) form of risk assessment that BAT was interested in. 
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that an opportunity therefore existed to press for: ‘More detailed guidance on the 
preparation of business impact assessments, perhaps including elements of structured risk 
assessment’ (Covington & Burling, 1996). Covington & Burling identified the UK government 
(which had already gone some way to incorporating risk assessment and Business IA into 
public policymaking) and the German government (which was perceived to be committed to 
reducing business-related regulations) as obvious policy allies in such a campaign. They also 
suggested that Nordic member states and ‘some non-business interest groups’ might be 
persuaded to support the proposals if they believed that they would help achieve more 
transparent policymaking, whilst Commission support could be optimised by linking the 
measure to the growth of SMEs (Covington & Burling, 1996). 
 
The documents suggest BAT managers were persuaded by the idea of using IA as a means of 
promoting risk assessment (e.g. Anonymous, 1997a; Gretton, 1998), a decision which appears 
to have marked the start of a broader strategy to deliberately construct a vaguely defined 
idea that could be strategically adapted to appeal to diverse constituencies.  Yet, rather than 
trying to embed risk assessment within fiches d’impact, as Covington & Burling had 
suggested, BAT committed itself to the more ambitious aim of using the Commission’s 
interest in revising its fiches d’impact guidelines as a foothold for a campaign which was 
intended to achieve nothing less than a paradigm shift in the way European regulation 
functioned (Chalfen, 1996d).  BAT’s strategy hinged on replacing fiches d’impact with a far 
more thorough and economically orientated form of Business IA, based on cost-benefit 
analysis (CBA), whilst working to promote the notion that risk assessment was a necessary 
part of this approach (e.g. Anonymous, 1997a; Chalfen, 1996d).  This was in no way an 
obvious strategy; not only were fiches d’impact silent on the issues of assessing risk and risk 
management (Commission of the European Communities, 1986b) but the process itself was 
relatively marginal to European policymaking (Froud et al., 1998).   
 
Focusing on IA offered a number of benefits to the company. By making economic 
assessments central to risk/benefit calculations (Bero, 2012), it was hoped that it might 
counter what BAT and its allies perceived to be an increasing use of the Precautionary 
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Principle in EU policymaking (BAT, 2000a; EPC, 1998; see above).  By enabling public officials 
to regulate in the absence of a clear scientific consensus over the risks of economic activity to 
public health and the environment (Martuzzi & Bertollini, 2005; Commission of the European 
Communities, 2000), the Precautionary Principle was widely regarded by EU businesses as 
subordinating economic growth and competitiveness to harm prevention (BAT, 2000a; EPC, 
1998; Löfstedt, 2002).  BAT managers conceived that incorporating risk assessment into CBA 
would provide a means of achieving precisely the opposite (Bero, 2012).  As one BAT 
document explains, the strategy aimed to ensure: ‘that new measures are not adopted unless 
they will achieve significant risk reductions at a reasonable cost, and to require that new 
regulations and legislation are based on quantitative risk assessment’ (BAT, 1996a).  The 
immediate commercial aim of the approach was to prevent the introduction of tobacco 
control measures, such as restrictions on tobacco advertising and legislation designed to limit 
second-hand smoke exposure, by creating minimum requirements for risks to health linked to 
the economic impact of proposed regulation (BAT, Undated-b).  In addition, the accountancy 
firm Ernst and Young advised BAT that the requirement for quantitative data in CBA might 
conceivably help establish a more resource-dependent relationship between BAT and EU 
officials: 
 
‘The lack of official statistics will mean that greater attention and credibility will be 
[given] to the industry developed statistical series.  This can be used to advantage in 
discussions and negotiations with government agencies as it means that the industry 
has access to information (potentially including economic assessment studies) that are 
unavailable to government officials.  Officials will often be more willing to talk to 
industry in these circumstances.’ (Ernst & Young, 1997) 
 
This is likely to have been particularly attractive to BAT in the context of the declining political 
authority and public credibility of tobacco industry interests (Fooks et al, 2013) as it seemed 
to allow the company to re-establish itself as a legitimate stakeholder in policy debates.  
Similarly, the calls for greater ‘transparency’ and ‘consultation’ within policymaking, 
associated with Better Regulation, were likely to have been helpful to BAT in securing their 
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inclusion in policymaking discussions ([BAT], 1997a; Anonymous, 1997a; Gretton, 1996b). 
Hence, an emphasis on consultation and transparency served the dual purpose of attracting 
policy actors committed to transparency, such as the Nordic Member States (see above), and 
providing a rationale for challenging tobacco industry exclusion from EU policymaking 
discussions.  
 
Although these various ideas (risk assessment, a form of IA modelled on CBA, and 
commitments to transparency and consultation) were not immediately labelled ‘Better 
Regulation’ by BAT or the EPC, the documents indicate that, from the start, they were 
considered part of the same project, and were presented as mutually reinforcing ([BAT], 
1997a; Ballantine & Crossick, 1996; Gretton, 1996b).  Promotional material therefore focused 
on collectively promoting risk assessment and CBA (as a form of Business IA), transparency 
and stakeholder consultation (Ballantine & Crossick, 1996). The ‘chameleonic’ qualities 
(Smith, 2013b) of the overall concept, originally mooted as ‘better legislation’3, allowed the 
reforms to be packaged differently according to the audience being targeted.   
 
First, concepts such as risk assessment and Business IA were simultaneously marketed as 
advantageous to the narrow interests of regulated industries and as a valuable component of 
socially efficient policymaking.  Thus, in letters to large corporations in other regulated 
sectors, Stuart Chalfen (a solicitor at BAT - see Table 2) described the campaign as ‘a unique 
opportunity’ to ‘protect in a fundamental manner the interests of European industry vis-à-vis 
the European regulators’ (Chalfen, 1996b).  Chalfen’s letter concluded that the proposed 
reforms represented ‘a remarkable step forward’ for regulated companies in the EU (Chalfen, 
1996b).  In contrast, an EPC occasional paper making the case for regulatory reform to a 
broader policy audience, produced following a suggestion that such a paper could usefully 
serve as a campaign ‘hook/crib sheet’ (Anonymous, 1996e), focused explicitly on CBA and only 
briefly mentioned risk.  The key point here is that, in marked contrast to Chalfen’s promise to 
                                                 
3 In 1997, some years before the concept of Better Regulation had become a familiar term in the EU, a 
consultant at the Weinberg Group (see Table 1), suggested to BAT that ‘better legislation’ might be a useful title 
for a conference promoting the regulatory reforms the company was hoping to achieve and stressed that, ‘The 
title, if we get it right, is the fundamental objective’ (Huggard, 1997). 
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other large corporations of fundamental regulatory reform, the EPC occasional paper simply 
presented CBA as a technical ‘management tool’ that could be used to improve transparency, 
accountability and ‘the quality of legislative and regulatory decision-making’ (Ballantine & 
Crossick, 1996).  The suggestion here was that such a tool would merely help policymakers to 
better understand ‘the full costs and benefits of government actions’ (Ballantine & Crossick, 
1996), rather than significantly change the relationship between industry and regulators or 
shape officials’ approach to assessing and managing risk. In other words, the way in which the 
regulatory reforms were pitched to policy audiences was markedly different from the manner 
in which Chalfen framed the reforms in correspondence with other regulated industries.   
 
Second, in-line with Covington & Burling’s advice, the reforms were initially pitched by the 
EPC as primarily benefiting SMEs, which fitted with the Commission’s aim of enhancing the 
competitiveness of smaller enterprises in the EU (EPC, 2001, 2004). This was despite the fact 
that the campaign was primarily orchestrated by, and designed to promote the interests of, 
large corporations in regulated sectors (see above and Figure 1), such as BAT4.  At a later 
stage, Charles Miller (of the Fair Regulation Campaign) then emphasised the need for the 
officials implementing Better Regulation reforms to focus on the needs of big business (Miller 
quoted in Gribben, 2000)5.   
 
Third, the reforms were presented in subtly different ways to appeal to different political 
audiences.  In 1996, for example, faxed documents from Covington & Burling suggest that, in 
the run up to the UK’s 1997 General Election, the coalition adapted the way in which the 
concepts were described to appeal to the perceived preferences of the two main, opposing 
parties, Labour and the Conservatives ([Covington & Burling], 1996a, 1996b).   
 
Finally, the chameleonic quality of the reforms enabled the campaign to respond to changing 
political circumstances.  In 1999, the European Commission was rocked by a scandal 
                                                 
4 In reality, SMEs are far less likely than large corporations to have sufficient resources to be able to benefit from 
the resource-dependent relationship that CBA helps create between policymakers and business. 
5 In practice, Better Regulation seems to have done little to have reduced the costs of regulation to SMEs 
(Baldwin, 2004).  
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concerning nepotism and cronyism and 20 Commissioners were forced to resign (CNN, 1999). 
The EPC subsequently focused on emphasising the aspects of the proposed reforms relating 
to ‘transparency’ and ‘accountability’, presenting Regulatory IA (a form of Business IA) as a 
means of addressing the perceived ‘democratic deficit’ in Europe (EPC, 2001). 
 
In focusing on the promotion of such a multifaceted and malleable concept (which became 
known as Better  Regulation), as opposed to the very narrow, specific form of risk assessment 
that BAT managers eventually hoped to achieve, it was possible for the campaign to be 
adapted to appeal to different audiences.  The strategies of developing a malleable concept 
and building a large coalition of support were therefore closely intertwined, with the 
chameleon-like qualities of Better Regulation helping to attract the diverse constituencies 
required for success, and the divergent support further contributing to the concept’s varying 
interpretations.  The EPC helped both to establish the broad-based corporate constituency in 
favour of the regulatory reforms and, over time, to attract policy officials and politicians to 
the coalition, facilitating the political traction of the coalition’s proposals.   
 
The major disadvantage of ‘chameleonic ideas’ is that their flexibility raises the risk that key 
sponsors may lose control of the agenda.  Reflecting this, BAT had, from the start, been 
warned that risk assessment guidelines ‘might be hijacked by other lobbies’, such as ‘the 
environmental lobby [which] might insist that sustainable development issues comprise one of 
the criteria in the assessment guidelines’ (MacKenzie-Reid, 1995).  This concern was not 
unwarranted. In 1997, for example, Crossick reported that the EU Directorate General 
responsible for health policy was establishing a separate risk assessment unit, reporting 
directly to the Director-General, which had plans to develop approaches to risk assessment 
that Crossick considered ‘political’ and ‘dangerous’ (Crossick, 1997). 
 
With a view to maintaining control over the campaign, BAT and EPC worked to construct a 
closed group within the EPC, helping ensure that expansion of the coalition did not 
necessarily dilute their ability to manage the direction of the campaign. In 1996, the EPC 
created the Risk Forum (EPC Risk Forum, 2006), the membership of which was dominated by 
In press: Journal of Health Politics, Policy and Law 
  
12 
BAT and the other large companies that had agreed to support the campaign. Significantly, 
according to our interview data, even though a number of non-governmental and civil society 
organisations were members of the EPC at this time, they were specifically excluded from the 
Risk Forum throughout its existence within the EPC (indeed, two interviewees involved in the 
campaign reported that it was as a result of pressure to allow other members of the EPC to 
join the Risk Forum that the Forum left the EPC in 2007 and established itself as the 
independent European Risk Forum – see Table 1).  This suggests that a ‘closed’ (invitation 
only) inner group was established within the broader coalition and that this approach was 
deemed crucial, probably because it allowed BAT and other major corporations to maintain 
some control over the direction of the campaign, even as support for ‘Better Regulation’ was 
evolving into a more institutionalised ‘advocacy coalition’, involving politicians and officials at 
EU and member state level.  The potential for the campaign’s ideas to be interpreted in 
multiple ways also explains why BAT took a closely managed approach to mobilising a 
coalition for regulatory reform, as outlined below. 
 
 
(iii) Working to achieve policy change 
The process of embedding the Forum’s broad interests into European policymaking was 
undertaken in stages and initially focused on inserting a Protocol into the Treaty of 
Amsterdam (a revision to the Treaty on European Union) which would make CBA a mandatory 
component of EU policymaking (BAT, Undated-a; Crossick, 1996b; interview with Crossick, 
18th September 2008).  To achieve this, the Forum’s members were encouraged to focus on 
mobilising support from public and elected officials in strategically important member states 
in advance of the inter-governmental conference that culminated in the Treaty of Amsterdam 
([BAT], Undated; [Risk Forum], Undated; Anonymous, 1997b; Chalfen, 1996d; Veljanovski, 
1996; interview with Crossick, 18th September 2008).  In practice, the strategy relied heavily 
on the EPC and supportive business organisations, notably UNICE (the Union of Industrial and 
Employers’ Confederations of Europe, subsequently renamed BusinessEurope – see Table 1), 
the CBI (Chalfen, 1998a, 1998b, 2000; Etherington, 1994), the Bundesverband der Deutschen 
Industrie (the German employers' federation), and the Irish Business and Employers 
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Confederation (Agar, 1997; Crossick, 1996c, 1996b, 1996a; Geoghegan, 1997; Kretschmer, 
1996; UNICE, 1996b; Woods, 1995). 
 
Lobbying efforts focused particularly on Member States where the ruling political parties 
were already predisposed to Business IA or CBA, such as the UK and Germany, although some 
other Member States were also targeted, notably the Irish and Dutch Governments which 
consecutively held the EU Presidency during the Inter-Governmental Conference 
(Anonymous, 1997a, 1997b; BAT, Undated-a, Undated-b; Covington & Burling, 1996; Gretton, 
1997). In Ireland, the UK and Germany, supportive trade associations appealed directly to 
government ministers (Geoghegan, 1997; Crossick, 1998b; Turner, 1998, Chalfen, 1996a; 
Kretschmer, 1996; Marcq, 1996; UNICE, 1996a). In Germany and the Netherlands, lobbying 
was directed via key industrialists with close personal links to senior policymakers 
(Anonymous, 1997a; Chalfen, 1997; Curtis, 1997; Hudig, 1997).  Both the EPC (EPC Risk 
Forum, 2006) and UNICE (UNICE, 1996b) made direct submissions to the Inter-Governmental 
Conference, calling for CBA to be made legally binding. 
 
Persuading the UK Government to act as an advocate on behalf of the Forum was considered 
particularly important.  BAT managers and the EPC considered the UK to be further along 
than other Member States in embedding Business IA into policymaking (Covington & Burling, 
1996; BAT, 1995). Documentary evidence (Gretton, 1996b, 1996a; Binning, 1996a, 1996b, 
1996c) and existing literature (Farnsworth, 2004; Farnsworth & Holden, 2006) suggest that 
this is likely to have been partly due to the influence that businesses, like BAT, had already 
exercised over regulatory policy in the UK. The focus on the UK and other Member States 
deemed likely to be supportive allowed the campaign to make use of the EU’s decentralised 
policy system, with its multiple points of influence (Coen, 2007).  This included enabling the 
coalition to target the Council of Ministers and thus representatives of EU Member States 
(see Figure 1). 
 
This first stage of the strategy, securing a change in the wording of the official Treaty on 
European Union was successful (BAT, Undated-b; EPC, 1997). The documents do not make 
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clear the extent to which BAT/EPC was formally involved in drafting the Protocol (which was 
tabled by the UK delegation) but BAT have several versions of the Protocol on their files 
(Anonymous, 1996a, 1996b, 1996c, 1996d, Undated).  The eventual wording of the sections of 
Treaty that BAT managers focused on was as follows: 
 
‘Without prejudice to its right of initiative, the Commission should: 
- Except in cases of particular urgency or confidentiality, consult widely before 
proposing legislation and wherever appropriate, publish consultation documents: 
- justify the relevance of its proposals with regard to the principle of subsidiarity; 
whenever necessary, the explanatory memorandum accompanying a proposal will give 
details in this respect. The financing of Community action in the whole or in part from 
the Community budget shall require an explanation; 
- take duly into account the need for any burden, whether financial or administrative, 
falling upon the Community, national governments, local authorities, economic 
operators and citizens, to be minimised and proportionate to the objective to be 
achieved.’ (BAT, Undated-b) 
 
Although it did not refer specifically to a requirement for CBA or IA, this section of text was 
interpreted by BAT to mean ‘the Commission must now take into account the financial and 
administrative burden (cost), which has to be minimised and proportionate to the objective 
(benefit)’ (BAT, Undated-b).  It is impossible to know whether the UK government already 
intended to include wording to the above effect in its submission; when interviewed, Crossick 
said that the EPC had suggested the inclusion of a requirement for CBA to various Member 
State representatives and that this suggestion was generally welcomed.  Whatever their level 
of involvement in the specific Treaty change, BAT managers considered it to be a major coup 
(BAT, Undated-b).  However, the chameleonic nature of the ideas used in the campaign, and 
the relatively imprecise wording of the protocol, inevitably widened the range of ways in 
which regulatory reform might subsequently evolve.  This necessitated sustained political 
activity aimed at narrowing the received meaning and legal interpretation of the Treaty 
change ([BAT], 1997b; [EPC], 1998; EPC, 1997; interview with Crossick, 18th September 2008). 
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The next stage of the campaign had at least three overlapping strands. The UK’s leadership of 
the six-monthly rotating EU Presidency was seen as an important ‘window of opportunity’ 
(BAT, Undated-a).  Hence, at EPC’s suggestion, one strand involved UNICE and the CBI directly 
lobbying the UK Prime Minister, Tony Blair, over the implementation of the Protocol ([EPC], 
1998; Crossick, 1997, 1998b, 1998c) and according to a note from Crossick (1998b), these 
efforts were received favourably.  The second strand centred on the organisation of a 
conference to promote the Forum’s favoured interpretation of the Protocol, which was that 
CBA was now a legal requirement in the EU and that ‘CBA must include risk assessment’ 
(Gretton, 1998).  The EPC and the Weinberg Group (an international consultancy firm which 
had been involved in a tobacco industry campaign to reform risk assessment in the USA – Ong 
& Glantz, 2001) approached David Clark MP (see Table 2) with a proposal for the UK to 
sponsor a conference on risk whilst it held the EU Presidency ([BAT], 1997a, 1997b; Huggard, 
1997).  Clark, who was the Minister responsible for regulatory reform in the UK at that time, 
and who had previously served as a political advisor to BAT (BAT, 1992), agreed to support 
the initiative6.  The conference, entitled ‘Managing Risk: A Balancing Act’, went ahead and 
was paid for by BAT, which also played a key role in selecting speakers and delegates and 
organising the associated promotional material ([BAT], 1997b; Curtis, 1998a, 1998b, 1998c; 
Crossick, 1998a).  Yet it was officially sanctioned by the UK Presidency of the EU and formal 
materials made little, if any, mention of BAT (Anonymous, 1998a; [BAT], 1997b, 1997a).  A 
third strand involved the CBI and BAT working with a number of other business interests to 
establish a second corporate group in January 1999, called the Fair Regulation Campaign (see 
Table 1).  This campaign specifically aimed to influence UK and European officials’ 
interpretations of the new Treaty Protocol (Miller, 1999; Anonymous, 1999).  Coordinated by 
Charles Miller of the Public Policy Unit (Tables 1 and 2), the Fair Regulation Campaign quickly 
won the support of a number of European Commissioners, including Erkki Liikanen, then 
Commissioner for Enterprise and Information (Summers, 2000a, 2000b; Fair Regulation 
Campaign, 2000; Business Europe, 2000; interview with Charles Miller on 27th August 2008). 
 
                                                 
6 It is unclear to what extent Clark knew of BAT’s involvement in the conference. 
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With the increasing support and involvement of officials and politicians, BAT’s original group 
of corporations steadily broadened into a rather more classic advocacy coalition, involving 
key politicians and policymakers as well as the large businesses, think tank and consultancy 
organisations initially involved.  This allowed the coalition to exert influence across the EU 
Commission, Parliament and Council (see Figure 1).  Although the range of actors involved 
reflected the considerable breadth of support for regulatory reform, support for the core 
ideas of Better Regulation was more sectoral than it might have appeared. In other words, 
the diversity of entities now working to move the issue forward is likely to have created a 
misleading impression amongst EU officials and other Member States concerning the depth of 
consensus in favour of the Better Regulation agenda (an interpretation supported by our 
interview data).  Obscuring the specific interests of the companies involved is likely to have 
helped attract policymakers and others (such as SMEs and civil society organisations), 
ensuring they were unaware of the extent to which a small group of large corporations were 
aiming to shape Better Regulation’s core concepts in their favour.  This is not to say, however, 
that those who supported the campaign did not agree with the need for regulatory reform or 
the potential benefits of IA, including that it might delay and prevent some EU legislation (see 
Radaelli and Meuwese, 2010). 
 
Commissioner Liikanen’s support proved crucial to formalising the EPC Risk Forum’s preferred 
interpretation of the Protocol into EU decision-making as Liikanen oversaw a pilot study of 
Business IA in the Commission (Enterprise Directorate-General, 2002), which reportedly 
involved the provision of a Fair Regulation Campaign check-list to all Directorate-Generals 
(Corporate Europe Observatory, 2001).  Additionally, the EPC Risk Forum (which was at that 
time chaired by BAT scientist, Christopher Proctor) was commissioned to produce an 
occasional paper entitled Regulatory Impact Analysis: Improving the quality of EU regulatory 
activity (EPC, 2001), which also contributed to the official pilot study.   
 
Tracking how the campaign progressed from 2001 onwards is complicated by the availability 
of substantially fewer internal tobacco company documents. Alternative sources of data, 
including interviews with EU policymakers and lobbyistsv, suggest that many of the key 
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elements of the campaign continued7, although in line with BAT’s original ambitions, there 
appears to have been more of a shift in emphasis towards trying to shape policy assessments 
of, and responses to, risks8.  Also, as described above, the Risk Forum now exists as an 
independent think tank (EPC, 2006; European Risk Forum, 2009) which is made up almost 
solely of tobacco and chemical industry interests9. 
 
An assessment of the current situation suggests that the Better Regulation agenda has been 
successfully adopted at EU level.  For example, units and Directorates of the Commission have 
been renamed to include Better Regulation (see Radaelli and Meuwese, 2010), the European 
Commission created an official website dedicated to Better Regulation (recently renamed 
Smart Regulation - http://ec.europa.eu/smart-regulation/index_en.htm) and, as Radaelli and 
Meuwese (2010) note, Better Regulation became a priority for the Lisbon agenda.  IA has 
been formally adopted (albeit it on a ‘soft law’ basis – see Alemanno, 2009), with Commission 
guidelines now requiring integrated IAs, which incorporate assessments (preferably 
quantitative) of key business, environmental and social impacts, to be produced for virtually 
all proposals (European Commission, 2002, 2005, 2009)10.  There is also a consensus that 
Better Regulation in the EU represents a qualitatively different approach to governance and 
that IAs are taken seriously, often more seriously than is the case in Member States (again, 
see Radaelli and Meuwese, 2010).  However, it is too early to assess whether the large, 
                                                 
7 In April 2004, for example, the Irish Business and Employers Confederation organised a conference on Better 
Regulation in Ireland attended by Bertie Ahern, then Prime Minister (Ahern, 2004). Ahern actively encouraged 
the Irish Business and Employers Confederation’s participation in the push for Better Regulation, accepting their 
offer to ‘oversee implementation’ of Better Regulation in Ireland.  This suggests that the coalition BAT helped 
create may be consolidating its ‘insider’ status within some Member States.   
8 For example, in 2006, the EPC Risk Forum responded to a European Commission Green Paper on the 
Transparency Initiative by arguing that the Minimum Standards for Consultation should be extended to enable 
stakeholders to inform proposed guidelines on risk assessment and the Precautionary Principle (EPC, 2006).    
9 Information about the membership of the European Risk Forum is not provided on the Forum’s website 
(although this information is now available for the EPC on its website).  However, according to Dirk Hudig, 
Chairman of the European Risk Forum, BAT remains a member and has been joined by two other tobacco 
companies, Philip Morris and Swedish Match (email received from Dirk Hudig on 17th February 2010). The other 
members of the European Risk Forum are all companies based in, or with strong links to, the chemical industry 
or are consultancy firms, such as the Weinberg Group. 
10 The European Parliament and the Council are also supposed to produce their own IAs for significant policy 
developments, although implementation has been far more problematic in these contexts.  
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European-based corporations involved in the coalition described in this paper have been able 
to benefit from the regulatory reforms as they hoped.  
 
 
Concluding discussion: 
This paper addresses an important gap in the current academic literature concerning the 
origins and evolution of Better Regulation in the EU by providing an account of large business 
efforts to shape and promote these regulatory reforms. Although the paper focuses on 
tobacco interests in particular, the similarities between the tobacco industry and other 
regulated sectors (Freudenberg. & Galea, 2008; and Brownell & Warner, 2009), including 
those industries working to limit regulation relating to climate change (see Oreskes and 
Conway, 2012), mean many of the paper’s policy implications stretch well beyond tobacco. 
 
From a policy perspective, our findings point to the way in which policy entrepreneurs can 
amplify their influence over regulatory policy by skilfully exploiting multiple access points at a 
distance, obscuring the interests involved in promoting particular policy ideas. The ease with 
which the EPC Forum and the Fair Regulation Campaign both appear to have been able to 
involve political élites in corporate-led campaigns is consistent with the argument, made 
elsewhere, that commercial consultancy organisations have become increasingly 
institutionalised within the EU policymaking system (Lahusen, 2002).  Our findings therefore 
reinforce calls for the Commission to maintain a mandatory register of interests (ALTER-EU, 
2006), and confirm the importance of ensuring that mechanisms aimed at making EU 
lobbying more transparent are co-ordinated across its institutions (Coen, 2007) and extended 
to think tanks.   
 
Of course, the promotion of an idea by a particular company/industry does not make it a ‘bad 
idea’ per se.  Nor is it necessarily the case that the apparent success of BAT’s campaign ‘is an 
indication of ‘power’, in the sense of victory in a business-government conflict’ (Woll, 2007; 
p58): it may simply represent the ‘convergence of business and government objectives’ that 
Woll (2007: p59) identifies as common to many European policy debates.  Indeed, the 
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economic orientation of the EU’s Lisbon agenda may eventually have led to an economically 
dominated form of IA being developed and incorporated into the EU policymaking process, 
even without the involvement of BAT and its allies. Despite this, two interviewees who 
worked at the Commission (interviewed in 2008) attributed the origins of the ‘Better 
Regulation’, and the Commission’s policy interest in IA, directly to the EPC; whilst Stanley 
Crossick (Table 2) stated that the EPC’s interest in ‘Better Regulation’ and IA had, in turn, 
originated from Stuart Chalfen of BAT (interview with Stanley Crossick on 18th September 
2008).  Whilst policy decisions rarely originate from one clear source, these interviews 
support our broader data in suggesting that BAT was highly influential in promoting this 
agenda in the EU.  This does not lead us to conclude that Better Regulation is necessarily a 
negative development from a public health perspective, but rather that policymakers and 
those interested in promoting and protecting public health (which the EU has a legal 
requirement to do – see Hervey et al, 2010) should at least be aware of why BAT has been 
working to influence Better Regulation and what its managers hoped to achieve.  When 
considering the policy interests and ambitions of a major tobacco corporation, it is important 
to stress (as outlined earlier) the considerable extent to which premature morbidity and 
mortality are caused by tobacco products in Europe (WHO Europe, 2007).  This means that 
efforts by a tobacco company to avoid legislation likely to reduce tobacco consumption must 
necessarily be understood as efforts which, if successful, are likely to result in higher than 
necessary levels of morbidity and mortality (Mackenbach et al, 2013).  
 
Indeed, four aspects of the way IA has been implemented in the EU suggest it may be offering 
at least some of the benefits to large companies that BAT hoped.  First, Löfstedt (2004) claims 
that the ‘regulatory pendulum’ swung away from the Precautionary Principle when integrated 
IA guidelines were officially introduced in the EU, shifting the burden of proof onto 
policymakers (i.e. policymakers were required to use IA to demonstrate that a regulated 
product causes enough harm to warrant intervention, as opposed to the onus being on 
business interests to prove their safety).  Second, the way in which IA is functioning in the EU 
is inevitably shaped by the context in which it is being implemented and, currently, that 
context is the Lisbon Agenda, which is clearly economic in orientation with a particular focus 
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on business competitiveness (see Radaelli and Meuwese, 2010).  Third, the Commission’s 
internal control body for IAs, the Impact Assessment Board, does not include any 
representative from the DG responsible for health.  This is notable, given that Radaelli and 
Meuwese (2010) claim the Board was chosen to reflect the main categories of impacts 
perceived to be important by the Commission.  Finally, independent reviews of IAs produced 
by the Commission have consistently found that economic impacts have received the most 
attention (Franz & Kirkpatrick, 2007; Wilkinson et al, 2004), with environmental and social 
(particularly health) impacts receiving far less consideration (Franz & Kirkpatrick, 2007; Salay 
& Lincoln, 2008; Ståhl, 2010).  Elsewhere, we explain how tobacco and chemical companies 
have tried to use IA specifically, and Better Regulation generally, to prevent and/or weaken 
policy proposals impacting on their respective interests (Smith et al, 2010).   
 
From a theoretical perspective, the story presented in this paper can be understood in terms 
of a struggle between competing civil society and corporate led coalitions. The former 
believed in the need for greater EU regulations to guard against social and environmental 
harms (including to health), whilst the latter believed that regulation of economic operators 
at EU level should be as limited as possible in order to promote competitiveness and free 
market ideals.  BAT’s concern with a perceived increase in EU regulatory activity, linked to the 
Precautionary Principle, seems to have been interpreted as an indication that the competing 
coalition was becoming powerful enough to threaten the commercial interests of regulated 
industries operating in the EU.  This is not to say that the health-environmental coalition was 
necessarily achieving a level of policy influence significant enough to threaten the business-
orientated coalition’s interests for, as Sabatier and Jenkins-Smith (1999) point out, coalition 
actors tend to view their opponents as more threatening and powerful than they often are.  
Whatever the reality, BAT managers worked to build a political constituency around 
regulatory reform that they hoped would shift the balance of power back towards business 
and economic interests.  These regulatory reforms included mandatory requirements for EU 
policymakers to undertake ex-ante IA and risk assessment and to consult with stakeholders at 
an early stage, all of which appear to have been perceived as ways of ensuring that the 
production of EU regulation would be slowed and that the business-orientated coalition 
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would have greater opportunities to influence policy proposals likely to affect their interests.  
The requirement to ‘consult widely’ also appears to have been a means of enhancing the 
‘significant resource dependency’ between officials and commercial interests that Coen 
(2007: p334) has identified as common within EU lobbying but which has been increasingly 
limited in tobacco-related contexts (WHO, 2003). 
 
The findings reflect several of the ACF’s core features, including the staged approach taken to 
achieving policy change, the long period over which ideas about Better Regulation developed, 
the involvement of actors from a variety of institutions (including policy bodies) in coalitions, 
and the efforts to influence policy via multiple venues at multiple levels.  However, the ACF 
says little about the role of individual corporate actors, third party consultants or resources in 
the management and mobilisation of coalitions, all three of which appear to have played an 
important role in the case study presented in this paper and all of which have previously been 
highlighted as important to EU-focused lobbying (e.g. Bouwen, 2002; Coen, 2007; Woll, 2007). 
In addition, like Compston and Madsen (2001) and Kübler (1998), our findings emphasise the 
importance of studying the characteristics of the ideas employed by advocacy coalitions to 
achieve policy change.  The ACF is certainly useful in understanding the coalition-forming 
approach that BAT took to promoting regulatory reform but it does little to illuminate BAT’s 
decision to envelop structured risk assessment (the company’s main aim) within a package of 
broader regulatory reforms, which were then marketed in contrasting ways to different 
audiences.  We therefore propose that the ACF might usefully be supplemented by ideational 
approaches to analysing policy change (see Béland, 2005; Kisby, 2007). More specifically, our 
findings indicate that ‘chameleonic’ ideas (Smith, 2013b) can play a crucial role in long-term 
efforts to effect policy change.  The malleability of chameleonic ideas can be used to attract 
actors with quite divergent interests to support what, by virtue of a shared terminology, 
appears to be the same idea, even though the various supportive actors may have rather 
different interpretations of what the idea entails.  This is not merely because the ideas in 
question are an amalgamation of different interests but because they are deliberately imbued 
with mercurial qualities which allows different actors to interpret the idea according to their 
own interests and context. ‘Better Regulation’, as Radaelli (2007a, pp.8-9) puts it, ‘is a 
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convenient language in which very different reform priorities can all sit together’, allowing 
‘both programmes that increase the political power of the business community and initiatives 
that reduce the power of special interest groups’ all to be interpreted as ‘Better Regulation’. 
This is revealing itself via the way in which policy commitments to improving regulation in the 
late 1990s have steadily given way to a renewed focus on deregulation and economic 
competitiveness (Radaelli, 2007b; Baldwin, 2006) and to a new tolerance of risk amongst 
policymakers (Dodds, 2006).  Effectively, this approach appears to have allowed the business-
coalition (led by BAT) to promote their preferred regulatory reforms without experiencing any 
significant opposition from the health-environmental coalition (the individuals we 
interviewed with public health and/or environmental interests reported being unaware of the 
‘Better Regulation’ agenda until it had been officially adopted in the EU).  The flip-side of this 
approach, from BAT’s point of view, is the ongoing possibility that the meaning of Better 
Regulation will evolve in directions other than those envisaged by company managers.   
 
The concept of ‘chameleonic ideas’ (Smith, 2013b) raises some difficult questions for the ACF 
as, one of the Framework’s foundations is a clear distinction between three different levels of 
belief (deep core, policy core and secondary).  Our analysis suggests that this rigid distinction 
overlooks the potential for policy ideas which are flexible enough to bridge different levels of 
belief.  In the case of Better Regulation, whilst promotional material targeted at policymakers 
presented the reforms as technical and bureaucratic (i.e. relating to secondary level beliefs), 
letters from BAT to other large corporations in regulated sectors sketched out a promise of 
far more fundamental reforms which would help determine the relative priority given to 
business interests vis-à-vis public health and environment interests within EU policy (i.e. 
policy core beliefs).   
 
It could be argued that aspects of our findings relate to the fact that the advocacy-coalition 
we describe was in what Sabatier and Jenkins-Smith (1999) call a ‘nascent’ (formative) stage, 
when ‘almost everyone’ supports a new concept because it sounds innately appealing but 
remains poorly-defined.  However, our data suggest that whilst ‘Better Regulation’ was a new 
concept, the regulatory reforms that it encompassed were intended to shift the balance of 
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power in relation to an existing policy-subsystem (in which two identifiable coalitions already 
existed).  Furthermore, Better Regulation appears to have been vaguely-defined not by 
circumstance but for very deliberate and strategic reasons. Nevertheless, as Better Regulation 
in the EU becomes more clearly defined and understood, and as information emerges about 
the associated costs and benefits of its implementation for different groups, we would expect 
actors to coalesce into more numerous and distinct coalitions, as Sabatier and Jenkins-Smith 
(1999) describe, consequently clarifying some of the underlying conflicts involved and 
creating (or re-creating) the kind of mature policy sub-system that ACF theorists usually focus 
on.  Indeed, more recent events and reports sponsored by public health civil society groups 
suggest this maturation is presently occurring for Better Regulation and IA in the EU (e.g. 
Smokefree Partnership, 2010a, 2010b; ASH, 2010).  We therefore believe the concept of 
chameleonic ideas represents an important explanatory device that complements the 
account of policy change developed in the ACF.   
 
Whilst further research is required to explore the origins, evolution and consequences of 
‘Better Regulation’ in the EU, the findings presented in this paper confirm Coen and 
Richardson’s (2009) observation that European pressure politics are often obscured.  The 
corporate interests involved in the campaign described in this paper were rarely perceived by 
interviewees to have been involved in shaping or promoting Better Regulation, and although 
the EPC was positioned as a driving force behind this agenda by many of our interviewees 
(including an ex-Health Commissioner), almost no-one reported observing any links between 
the EPC and tobacco interests.  This suggests that, for the EU’s Transparency Register to be 
effective in helping to address the EU’s ‘democratic deficit’, it needs to be both mandatory 
and more closely monitored than is currently the case (Greenwood and Dreger, 2013), 
particularly with regards to organisations such as ‘consultants’ and ‘think tanks’, which may 
be acting on behalf of other interests.  In addition, the fact that BAT managers believed a 
form of IA modelled on CBA would work to slow down public health legislation in the EU and 
its member states, suggests far more attention needs to be given to exploring how tools such 
as this, which are ostensibly about increasing the use of evidence within decision-making, 
operate in practice.  At the very least, from a public health perspective, it seems crucial to 
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ensure that health policy interests are better represented on the Impact Assessment Board, 
the official forum for monitoring the European IA process. 
 
 
Funding and acknowledgements 
We would like to thank all of the interviewees who participated in this research, Cathy Flower 
for administrative support and two anonymous reviewers and Professor Colleen Grogen for 
helpful comments on an earlier version of this article. This work was supported by the Smoke 
Free Partnership (SFP) through a CR-UK grant (CR-UK is one of the SFP partners 
(www.cancerresearchuk.org), the others (at the time of the grant) being the European 
Respiratory Society (ERS at www.ersnet.org), and the Institut National du Cancer (INCa at 
www.e-cancer.fr). The research reported in this publication was also supported from the 
National Cancer Institute of the US National Institutes of Health (Grant Number 
RO1CA160695) and Cancer Research UK (Grant Number C27260/A8861). KS is supported by 
an Economic and Social Research Council Future Research Leaders Award (grant number: 
ES/K001728/1). The funders had no influence on the research design, data collection, data 
interpretation or the writing of this article.  
 
 
In press: Journal of Health Politics, Policy and Law 
  
25 
References 
Agar, Peter. 1997. Single Market Action Programme. (Bates number(s): 700512987-
700512999). Source: BAT. URL: http://bat.library.ucsf.edu//tid/gej23a99  (accessed 19 
Jun 2008). 
Alemanno, Alberto. 2009. “The Better Regulation Initiative at the Judicial Gate: A Trojan 
Horse within the Commission’s Walls or the Way Forward?” European Law Journal 
15(30): pp. 382-401. 
Allio, Lorenzo. 2007. “Better regulation and impact assessment in the European Commission”. 
In Regulatory Impact Assessment - Towards Better Regulation? , edited by Colin 
Kirkpatrick and David Parker, 72-105. Cheltenham: Edward Elgar Publishing. 
Allio, Lorenzo, Ballantine, Bruce, & Meads, Richard. 2005. “Enhancing the Role of Science in 
the Decision-making of the European Union”. Regulatory Toxicology and 
Pharmacology 44: 4-13. 
ALTER-EU (Alliance for Lobbying Transparency and Ethics Regulation). 2006. About ALTER-EU. 
URL: http://www.alter-eu.org/en/system/files/files/alter-
eu/publications/COE_Broschure_07-WEB.pdf (accessed 10 Sep 09). 
Anonymous. 1996a. Proposal for a Protocol on the Application of the Principle of Subsidiarity 
(Bates number(s): 700513238-700513258). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/mfj23a99 (accessed 02 Jun 2008). 
Anonymous. 1996b. Proposal for a Protocol on the Application of the Principle of Subsidiarity 
(Bates number(s): 700513226-700513237). Source: BAT. 
URL:http://bat.library.ucsf.edu//tid/lfj23a99 (accessed 29 May 2008). 
Anonymous. 1996c. Protocol Concerning the Requirement for Cost-Benefit Analysis of 
Measures Proposed by the Commission (Bates number(s): 800102627-800102628). 
Source: BAT. URL:http://bat.library.ucsf.edu//tid/cif14a99 (accessed 30 May 2008). 
Anonymous. 1996d. Protocol Concerning the Requirement for Cost-Benefit Analysis of 
Measures Proposed by the Commission* (Bates number(s): 700513415-700513418). 
Source: BAT 
Anonymous. 1996e. Risk Assessment. (Bates number(s): 700513980-700513986). Source: BAT. 
URL: http://bat.library.ucsf.edu//tid/xfj23a99 (accessed 02 Jun 2008). 
Anonymous. 1997a. Cost Benefit Analysis and Risk Assessment Working Group (Bates 
number(s): 700513505-700513514). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/ggj23a99 (accessed 30 May 2008). 
Anonymous. 1997b. Cost Benefit Analysis and Risk Assessment Working Group (Note of 
Meeting Oct 1997) (Bates number(s): 321573259-321573260). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/cgg63a99 (accessed 03 Jun 2008). 
Anonymous. 1998a. Managing Risk: A Balancing Act. (Bates number(s): 321574681-
321574686). Source: BAT. URL: http://bat.library.ucsf.edu//tid/ang63a99 (accessed 30 
May 2008). 
Anonymous. 1998b. “The Brussels lobbyist and the struggle for ear-time.” The Economist, 
348(8081): 42. 
Anonymous 1999. Fair Regulation Initiative: Campaign Group Presentation: 27 January 1999. 
(Bates number(s): 321332622-321332638). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/zuy23a99 (accessed 30 Jul 2008). 
In press: Journal of Health Politics, Policy and Law 
  
26 
Anonymous. Undated. Protocol on the Application of the Principle of Subsidiarity and 
Proportionality (Bates number(s): 325123249-325123251). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/ric53a99 (accessed 02 Aug 2008). 
ASH. 2010. The smoke filled room: How big tobacco influences health policy in the UK. London: 
ASH. URL: http://ash.org.uk/files/documents/ASH_726.pdf. 
Baldwin, Robert. 2006. “Better Regulation in Troubled Times.” Health Economics, Policy and 
Law, 1 (3): 203-7. 
Ballantine, Bruce and Crossick, Stanley. 1996. The Need for Cost-Benefit Analysis. (Bates 
number(s): 800102696-800102703). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/mif14a99 (accessed 24 Jul 2008). 
BAT. 1992. Report on CPC note. (Bates number(s): 201072501-201072756). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/vmh45a99 (accessed 18 Jun 2008). 
BAT. 1995. ETS Pilot Study. (Bates number(s): 700875991-700876043). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/kwj63a99 (accessed 24 Jul 2008). 
BAT. 1996a. EU Issues. (Bates number(s): 322122073-322122107). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/pwt63a99 (accessed 05 Jun 2008). 
BAT. 2000a. Corporate Conduct and Orderly Markets. (Bates number(s): 322253332-
322253355). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/tfm55a99 (accessed 
30 Jul 2008). 
BAT. Undated-a. Risk Assessment Forum (Bates number(s): 321573210-321573213). Source: 
BAT. URL: http://bat.library.ucsf.edu//tid/mfg63a99 (accessed 04 Jun 2008). 
BAT. Undated-b. Shaping the Regulatory Environment: Advertising and Public Smoking. (Bates 
number(s): 322121140-322121143). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/xnz82a99 (accessed 23 May 2008). 
[BAT]. 1997a. Cost Benefit Analysis and Risk Assessment Working Group (Note of Meeting Oct 
1997) (Bates number(s): 321573259-321573260). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/cgg63a99 (accessed 03 Jun 2008). 
[BAT]. 1997b. Conference Evaluation Risk: A Balancing Act (Bates number(s): 321573216-
321573217). Source: BAT. URL: http://bat.library.ucsf.edu//tid/ofg63a99 (accessed 19 
Jun 2008). 
[BAT]. Undated. Cost-Benefit Analysis and Risk Assessment Strategy (Bates number(s): 
800102460-800102462). Source: BAT. URL: http://bat.library.ucsf.edu//tid/ahf14a99 
(accessed 16 Jun 2008). 
Béland, Daniel. 2005. “Ideas and Social Policy: An Institutionalist Perspective.” Social Policy 
and Administration, 39(1): 1-18. 
Bero, Lisa A. 2012. “Tobacco Industry Manipulation of Research on Environmental Tobacco 
Smoke.” Late Lessons from Early Warnings Volume 2. Copenhagen: The European 
Environment Agency. 
Better Regulation Task Force. 2005. Less is More - Reducing Burdens, Improving Outcomes, A 
BRTF report to the Prime Minister. London: Better Regulation Task Force. 
Binning, Kenneth. 1996a. Memo from K Binning to K Gretton regarding risk assessment 
document (Bates number(s): 800103592). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/qjt14a99 (accessed 08 Jul 2008). 
In press: Journal of Health Politics, Policy and Law 
  
27 
Binning, Kenneth. 1996b. Policy Appraisal and Health. (Bates number(s): 800103543-
800103545). Source: BAT. URL: http://bat.library.ucsf.edu//tid/mjt14a99 (accessed 09 
Jul 2008). 
Binning, Kenneth. 1996c. Risk Assessment and all that. (Bates number(s): 800102512). Source: 
BAT. URL: http://bat.library.ucsf.edu//tid/ghf14a99 (accessed 08 Jul 2008). 
Boardman, Anthony E., Greenberg, David H., Vining, Aiden R. and Weimer, David L. 2006. 
Cost-benefit Analysis: Concepts and Practice (3rd edition). New York: Prentice Hall.  
Bouwen, Pieter. 2002. “Corporate lobbying in the European Union: the logic of access.” 
Journal of European Public Policy, 9(3): 365-90. 
British Medical Association. 1999. Health and environmental impact assessment. An 
integrated approach. London: Earthscan Publications. 
Broscheid, Andreas and Coen, David. 2003. “Insider and Outsider Lobbying of the European 
Commission: An Informational Model of Forum Politics.” European Union Politics 4(2): 
165-89. 
Brownell, Kelly D. and Warner, Kenneth E. 2009. “The Perils of Ignoring History: Big Tobacco 
Played Dirty and Millions Died. How Similar Is Big Food?” The Milbank Quarterly, 
87(1):259-94. 
BusinessEurope. Undated. EU Better Regulation Agenda. URL: 
http://www.businesseurope.eu/content/default.asp?PageID=568&DocID=26890   
Cabinet Office. 1997. News Release 46/97 ‘Better regulation – not deregulation’, 3 July 1997. 
Carroll, Peter. 2010. “Does regulatory impact assessment lead to better policy?” Policy & 
Society, 29: 113-22. 
Chalfen, Stuart. 1996a. Letter from Stuart Chalfen to Fiona Marcq regarding cost benefit 
analysis. (Bates number(s): 800102471). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/bhf14a99 (accessed 01 Aug 2008). 
Chalfen, Stuart. 1996b. Letter from SP Chalfen to Jean-Francois Guillemin regarding quality of 
regulation in the European Union. (Bates number(s): 700513842-700513843). Source: 
BAT. URL: http://bat.library.ucsf.edu//tid/fhj23a99 (accessed 02 Jun 2008). 
Chalfen, Stuart. 1996c. Note from regarding meeting at Brussels offices. (Bates number(s): 
800102517-800102522). Source: BAT. URL:http://legacy.library.ucsf.edu/tid/hhf14a99 
(accessed 01 Aug 2008). 
Chalfen, Stuart. 1996d. Note from Stuart P Chalfen to Philippe Bocken regarding risk 
assessment and cost benefit analysis. (Bates number(s): 700513775-700513779). 
Source: BAT. URL: http://bat.library.ucsf.edu//tid/vgj23a99 (accessed 02 Jun 2008). 
Chalfen, Stuart. 1997. Letter from Stuart Chalfen to DF Hudig regarding CBA and risk 
management (Bates number(s): 321573148-321573149). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/cgf61a99 (accessed 04 Jun 2008). 
Chalfen, Stuart. 1998a. Letter from Stuart Chalfen to David Clark regarding conference on "a 
better Government more effective regulation". (Bates number(s): 322121117-
322121118). Source: BAT. URL: http://bat.library.ucsf.edu//tid/ydt14a99 (accessed 18 
Jun 2008). 
Chalfen, Stuart. 1998b. Note from Stuart Chalfen to Michael Prideaux regarding analysis in 
legislation and regulation in Europe. (Bates number(s): 322121138). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/xdt14a99 (accessed 18 Jun 2008). 
In press: Journal of Health Politics, Policy and Law 
  
28 
Chalfen, Stuart. 2000. [Letter from Stuart Chalfen to David Byrne regarding quality of 
regulation]. (Bates number(s): 325128165-325128166). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/cqi61a99 (accessed 28 May 2008). 
Chichilnisky, Graciela. 1997. “The costs and benefits of benefit-cost analysis.” Environment 
and Development Economics, 2: 202–5. 
Clark, David. 1997. Risk Assessment Seminar (Bates number(s): 321573214). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/nfg63a99 (accessed 18 Jun 2008). 
CNN. 1999. EU in turmoil after executive commission resigns. 
http://www.cnn.com/WORLD/europe/9903/16/eu.commission.01/ (accessed 06 Oct 
2008): CNN. 
Coen, David. 1998. The European Business Interest and the Nation State: Large-firm Lobbying 
in the European Union and Member States. Journal of Public Policy 18(1): 75–100. 
Coen, David. 2007. Lobbying in the European Union  - Briefing Paper. Brussels: Directorate-
General Internal Policies Policy Department C (Citizens Rights and Constitutional 
Affairs). 
Coen, David. 2007. “Empirical and theoretical studies in EU lobbying.” Journal of European 
Public Policy, 14(3): 333-45. 
Coen, David and Richardson, Jeremy. 2009 “Learning to Lobby the European Union: 20 Years 
of Change”. In Lobbying the European Union: Institutions, Actors, and Issues, edited by 
David Coen and Jeremy Richardson. Oxford: Oxford University Press. 
Commission of the European Communities. 1986a. Draft Resolution of the Council concerning 
the action programme for SME (COM 86 (445) Final). Brussels: Commission of the 
European Communities. 
Commission of the European Communities. 1986b. SME Impact Assessment Form for 
Commission Legislative Proposals (Communication from Mr Matutes) SEC86(290). 
Brussels: Commission of the European Communities. 
Commission of the European Communities. 1993. Growth, Competitiveness, Employment: The 
Challenges and Ways Forward into the 21st Century - White Paper COM(93) 700. 
Brussels: European Commission. 
Commission of the European Communities. 2000. Communication from the Commission on 
the precautionary principle COM(2000) 1 final. Brussels: Europa. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2000:0001:FIN:EN:PDF (accessed 
25 May 2010). 
Commission of the European Communities. 2002. Communication from the Commission - 
Action plan "Simplifying and improving the regulatory environment" COM(2002) 278 
final. Brussels: Europa. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2002:0278:FIN:EN:PDF (accessed 
06 Apr 2009). 
Commission of the European Communities. 2005. Communication from the Commission to the 
Council and the European Parliament - Better Regulation for Growth and Jobs in the 
European Union (SEC(2005) 175). Brussels. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2005:0097:FIN:EN:PDF (accessed 
06 Apr 2009): Commission of the European Communities. 
Commission of the European Communities. 2009. Communication from the Commission to the 
European Parliament, the Council, the European Economic and Social Committee and 
In press: Journal of Health Politics, Policy and Law 
  
29 
the Committee of the Regions - Third strategic review of Better Regulation in the 
European Union COM(2009) 15 final. Brussels and online at: 
http://ec.europa.eu/governance/better_regulation/documents/com_2009_0015_en.
pdf (accessed 02 Sep 2009): European Commission. 
Compston, Hugh and Madsen, Per K. 2001. Conceptual Innovation and Public Policy: 
Unemployment and Paid Leave Schemes in Denmark. Journal of European Social 
Policy, 11(2):117-32. 
Corporate Europe Observatory. 2001. "Better Regulation" - For Who? EC Prepares to 
Dismantle Business Regulation and Expand Corporate Control. URL: 
http://archive.corporateeurope.org/observer9/regulation.html#14 (accessed 19 May 
2010). 
Covington & Burling. 1996. EC Risk Assessment Proposal. (Bates number(s): 800103063-
800103065). Source: BAT. URL: http://bat.library.ucsf.edu//tid/hjt14a99 (accessed 12 
Jul 2008). 
[Covington & Burling]. 1996a. The Role of Cost Benefit Analysis in Implementing Health and 
Safety Regulation: The Need for a Change of Approach (Bates number(s): 800148207-
800148209). Source: BAT. URL: http://bat.library.ucsf.edu//tid/rvt72a99 (accessed 03 
Jul 2008). 
[Covington & Burling]. 1996b. The Role of Cost Benefit Analysis in Implementing Health and 
Safety Regulation: The Need for a Change of Approach (Bates number(s): 800148210-
800148212). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/svt72a99 (accessed 
22 Aug 2008). 
Crossick, Stanley. 1996a. Cost-Benefit Analysis (CBA) (Bates number(s): 800102625). Source: 
BAT. URL: http://legacy.library.ucsf.edu/tid/aif14a99 (accessed 07 Sep 2009). 
Crossick, Stanley. 1996b. Cost-Benefit Analysis (CBA): State of Play. (Bates number(s): 
800102689-800102691). Source: BAT. URL: http://bat.library.ucsf.edu//tid/jif14a99 
(accessed 30 May 2008). 
Crossick, Stanley. 1996c. Risk Assessment Project. (Bates number(s): 700513813-700513841). 
Source: BAT. URL: http://bat.library.ucsf.edu//tid/ehj23a99 (accessed 02 Jun 2008). 
Crossick, Stanley. 1997. CBA (Bates number(s): 700514111-700514120). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/dij23a99 (accessed 25 Aug 2008). 
Crossick, Stanley. 1998a. Follow-Up of Yesterday's Forum Meeting. (Bates number(s): 
321574397-321574398). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/tkg63a99 
(accessed 28 Jul 2008). 
Crossick, Stanley. 1998b. Note of 30 April Forum Meeting. (Bates number(s): 321574344-
321574347). Source: BAT. URL: http://bat.library.ucsf.edu//tid/fkg63a99 (accessed 05 
Jun 2008). 
Crossick, Stanley. 1998c. Risk Assessment: CBI/UNICE. (Bates number(s): 321574580-
321574581). Source: BAT. URL: http://bat.library.ucsf.edu//tid/aif61a99 (accessed 05 
Jun 2008). 
Curtis, Sarah. 2008. “How Can We Address Health Inequality Through Healthy Public Policy in 
Europe?” European Urban and Regional Studies, 15(4): 293-305. 
Curtis, Vickie. 1997. Note from Vickie Curtis to Stanley Crossick regarding cost benefit analysis 
& risk assessment group in Brussels. (Bates number(s): 700513967-700513968). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/lhj23a99 (accessed 01 Aug 2008). 
In press: Journal of Health Politics, Policy and Law 
  
30 
Curtis, Vickie. 1998a. Media Contacts for Conference. (Bates number(s): 321574633-
321574635). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/omg63a99 (accessed 
28 Jul 2008). 
Curtis, Vickie. 1998b. Minutes of Last Meeting. (Bates number(s): 321574135). Source: BAT. 
URL: http://bat.library.ucsf.edu//tid/cjg63a99 (accessed 04 Jun 2008). 
Curtis, Vickie. 1998c. Risk Conference - Things to Do! (Bates number(s): 321574592-
321574594). Source: BAT. URL: http://bat.library.ucsf.edu//tid/emg63a99 (accessed 
04 Jun 2008). 
Department for Business, Enterprise & Regulatory Reform. 2007. Next Steps on Regulatory 
Reform. London: Department for Business, Enterprise & Regulatory Reform. URL: 
http://www.berr.gov.uk/files/file44370.pdf (accessed 06 Apr 2009). 
Department of the Taoiseach. 2004. Regulating Better - A Government White Paper setting 
out six principles of Better Regulation. Dublin: Department of the Taoiseach. URL: 
http://www.betterregulation.ie/attached_files/upload/static/RegulatingBetterGovern
mentWhitePaper.pdf (accessed 06 Apr 2009). 
Department of Trade and Industry. 1985. Burdens on Business - Report of Scrutiny of 
Administrative and Legislative Requirements. London: HMSO. 
Department of Trade and Industry. 1988. Releasing Enterprise - Government action to free 
business and enterprise from regulations and red tape. London: DTI. 
Dodds, Anneliese. 2006. “The Core Executive's Approach to Regulation: From 'Better 
Regulation' to 'Risk-Tolerant Deregulation'.” Social Policy & Administration, 40(5): 526-
42. 
Driesen, David M. 2006. Is Cost-Benefit Analysis Neutral?. University of Colorado Law Review, 
77: 335-405. 
Enterprise Directorate-General. 2002. Business impact assessment pilot project Final report – 
Lessons learned and the way forward (Enterprise Papers No 9). Brussels. URL: 
http://ec.europa.eu/enterprise/library/enterprise-
papers/pdf/enterprise_paper_09_2002.pdf (accessed 25 Aug 2008). 
EPC. 1997. Briefing Paper on Risk Assessment (Bates number(s): 321573155). Source: BAT. 
URL: http://legacy.library.ucsf.edu/tid/weg63a99 (accessed 02 Apr 2009). 
EPC. 1998. Forum on Risk: Brussels 12 March 1998. (Bates number(s): 321574226-
321574232). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/qhf61a99 (accessed 
02 Aug 2008). 
EPC. 2001. Regulatory Impact Analysis: Improving the Quality of EU Regulatory Activity. 
Brussels. URL: http://ec.europa.eu/governance/contrib_epc_en.pdf (accessed 25 Aug 
2008). 
EPC. 2004. Achieving a New Regulatory Culture in the European Union: An Action Plan 
(Working Paper No.10). Brussels: EPC. URL: 
http://www.epc.eu/TEWN/pdf/992514580_EPC%20Working%20Paper%2010%20Achi
eving%20a%20new%20Regulatory%20Culture%20in%20the%20European%20Union.p
df (accessed 26 Jun 2009). 
EPC. 2006. European Commission Green Paper ‘European Transparency Initiative’ – Feedback 
on Application of the Minimum Standards for Consultation. Comments by European 
Policy Centre. URL: 
In press: Journal of Health Politics, Policy and Law 
  
31 
http://ec.europa.eu/transparency/eti/docs/contributions/95_C3_Ch2_EPC.pdf 
(accessed 19 May 2010). 
EPC. 2009. About EPC - Financing. 
http://www.epc.eu/en/ae.asp?TYP=ABOUT&LV=224&see=n&PG=AE/EN/fin&AI=35 
(accessed 15 Apr 2009): European Policy Centre (EPC). 
[EPC]. 1998. Forum on Risk: Brussels 12 March 1998. (Bates number(s): 321574226-
321574232). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/qhf61a99 (accessed 
02 Aug 2008). 
EPC Risk Forum. 2005. Enhancing the role of science in the decision-making of the European 
Union (EPC Working Paper 17). Brussels: EPC. URL: 
http://www.epc.eu/TEWN/pdf/668109152_EPC%20Working%20Paper%2017%20Enh
ancing%20the%20role%20of%20science%20in%20EU%20decision%20making%20(revi
sed).pdf (accessed 25 Aug 2008). 
EPC Risk Forum. 2006. Comments on the European Commission Green Paper: “Promoting 
Healthy Diets and Physical Activity: A European Dimension for the Prevention of 
Overweight, Obesity, and Chronic Diseases” (2005). URL: 
http://ec.europa.eu/health/ph_determinants/life_style/nutrition/green_paper/nutriti
ongp_co050_en.pdf (accessed 25 Aug 2008). 
Ernst & Young. 1997. British-American Tobacco Company Limited: Economic Impact 
Assessment Template and Routemap. (Bates number(s): 700642348-700642407). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/aax92a99 (accessed 02 Aug 2008). 
Etherington, Ken. 1994. CBI: Letter 9/12/94 from Peter Agar. (Bates number(s): 202604724). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/gsk48a99 (accessed 15 Aug 2008). 
EU Presidencies. 2004. Advancing Regulatory Reform in Europe - A joint statement of the Irish, 
Dutch, Luxembourg, UK, Austrian and Finnish Presidencies of the European Union. URL: 
http://www.hm-treasury.gov.uk/d/advancing_regulatory_reform_in_europe.pdf 
(accessed 06 Apr 2009). 
European Commission. 2002. Communication from the Commission on Impact Assessment 
COM(2002) 276 Final. Brussels. URL: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2002:0276:FIN:EN:PDF (accessed 
on 30 Dec 2008): Europa 2002. 
European Commission. 2005. Impact Assessment Guidelines SEC(2005) 791. Brussels: Europa. 
URL: 
http://ec.europa.eu/governance/impact/docs/SEC2005_791_IA%20guidelines_annexe
s.pdf (accessed on 02 Sep 2008). 
European Commission. 2009. Impact Assessment Guidelines SEC(2009) 92. Brussels: Europa. 
URL: http://ec.europa.eu/governance/impact/docs/key_docs/iag_2009_en.pdf 
(accessed 01 Apr 2009). 
European Risk Forum. 2009. European Risk Forum. Brussels: European Risk Forum. URL: 
http://www.euportal2.be (accessed 15 Apr 2009). 
Fair Regulation Campaign. 2000. Business Impact Assessment: Fair Regulation Campaign/ 
Eurochambres Hearing 28 November 2000. (Bates number(s): 322239539-322239548). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/whw23a99 (accessed 29 Jul 2008). 
Farnsworth, Kevin. 2004. Corporate Power and Social Policy in a Global Economy: British 
Welfare Under the Influence. Bristol: Policy Press. 
In press: Journal of Health Politics, Policy and Law 
  
32 
Farnsworth, Kevin and Holden, Chris. 2006. “The Business-Social Policy Nexus: Corporate 
Power and Corporate Inputs into Social Policy.” Journal of Social Policy 35(3): 473-94. 
Farquharson, Karen. 2003. Influencing policy transnationally: pro- and anti-tobacco global 
advocacy networks, Australian Journal of Public Administration, 62(4): 80–92. 
Fitzsimons, Lorna. 1995. Project 2. (Bates number(s): 900001360-900001361). Source: BAT. 
URL: http://legacy.library.ucsf.edu/tid/eao04a99 (accessed 12 Aug 2008). 
Fooks, Gary, Gilmore, Anna, Collin, Jeff, Holden, Chris and Lee, Kelley. 2013. “The limits of 
corporate social responsibility: Techniques of neutralization, stakeholder management 
and political CSR.” Journal of Business Ethics, 112(2):283-99. 
Franz, Jennifer and Kirkpatrick, Colin. 2007. “Integrating Sustainable Development into 
European Policymaking: The Role of Impact Assessments.” Journal of Environmental 
Assessment Policy and Management 9(2):141-60. 
Freudenberg, Nicholas and Galea, Sandro. 2008. The impact of corporate practices on health: 
implications for health policy. Journal of Public Health Policy 29(1):86-104. 
Froud, Julie, Boden, Rebecca, Ogus, Anthony and Stubbs, Peter. 1998. Controlling the 
Regulator. Basingstoke: Palgrave Macmillan. 
Geoghegan, Brian. 1997. Regulatory Impact Assessment. (Bates number(s): 700513000-
700513005). Source: BAT. URL: http://bat.library.ucsf.edu//tid/hej23a99 (accessed 19 
Jun 2008). 
Gilmore, Anna and McKee, Martin. 2004. “Tobacco-control policy in the European Union.” In 
Unfiltered: Conflicts over tobacco policy and public health, edited by Eric A. Feldman 
and Ronald Bayer. Cambridge, Massachusetts: Harvard University Press. 
Greenwood, Justin and Dreger, Joanna. 2013. “The Transparency Register: A European 
vanguard of strong lobby regulation?” Interest Groups & Advocacy, 2(2): 139–62. 
Gretton, Keith. 1996a. Risk Assessment in the UK and Europe - Achieving a more disciplined 
and rigorous approach by Government to risk assessment (Bates number(s): 
800102491-800102498). Source: BAT. URL: http://bat.library.ucsf.edu//tid/hns14a99 
(accessed 08 Jul 2008). 
Gretton, Keith. 1996b. Risk Assessment Progress (Bates number(s): 800147892-800147900). 
Source: BAT. URL: http://bat.library.ucsf.edu//tid/cvb53a99 (accessed 03 Jun 2008). 
Gretton, Keith. 1997. Risk Assessment Meeting. (Bates number(s): 700513969-700513973). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/mhj23a99 (accessed 01 Aug 
2008). 
Gretton, Keith. 1998. Visit to the UK. (Bates number(s):321574638-321574639). Source: BAT. 
URL: http://legacy.library.ucsf.edu/tid/pmg63a99 (accessed on: 21 Jun 2010). 
Gribben, Roland. 2000. “EU rules questioned.” The Telegraph 9th October 2000. URL: 
http://www.telegraph.co.uk/finance/4467989/EU-rules-questioned.html (accessed 19 
May 2010). 
Hahn, Robert W. and Litan, Robert E. 1997. Improving regulatory accountability. Washington, 
D.C.: American Enterprise Institute for Public Policy Research and the Brookings 
Institution. 
Hervey, Tamara, McKee, Martin and Gilmore, Anna. 2010. “Public health policies” In Health 
systems governance in Europe: the role of EU law and policy, edited by Elias Mossialos, 
Govin Permanand, Rita Baeten and Tamara Hervey, 231-81. Cambridge: Cambridge 
University Press. 
In press: Journal of Health Politics, Policy and Law 
  
33 
Hirschhorn, Nobert and Bialous, Stella A. 2001. “Second hand smoke and risk assessment: 
what was in it for the tobacco industry?” Tobacco Control, 10: 375-82. 
Honour, Heather. 1996. Risk Assessment (Bates number(s): 800103062). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/fjt14a99 (accessed 24 Jul 2008). 
Hudig, Dirk F. 1997. Commission Guidelines for Legislative Policy. (Bates number(s): 
800147880-800147889). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/qut72a99 (accessed 01 Aug 2008). 
Huggard, Joeseph A. 1997. Programme (Bates number(s): 321573170-321573173). Source: 
BAT. URL: http://legacy.library.ucsf.edu/tid/afg63a99 (accessed 15 Apr 2009). 
IMPACT. 1995. Impact Assessments: Changing the Way Business Deals with Government. 
(Bates number(s): 800103160-800103167). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/fjf14a99 (accessed 24 Jul 2008). 
Jarvis, Andrew. 2012. A study on liability and the health costs of smoking DG SANCO 
(2008/C6/046) Updated final report (April 2012). Submitted by GHK in association with 
the University of Exeter (UK) and the Public Health Advocacy Institute (USA). London: 
GHK. URL: http://ec.europa.eu/health/tobacco/docs/tobacco_liability_final_en.pdf. 
Kelman, Steven. 1981. “Cost-benefit analysis: an ethical critique.” AEI Journal on Government 
and Society Regulation: 33–40. 
Kisby, Ben. 2007. “Analysing Policy Networks: Towards an Ideational Approach.” Policy 
Studies, 28(1): 71-90. 
Kopp, Raymond J., Krupnick, Alan J. and Toman, Michael. 1997. Cost-benefit analysis and 
regulatory reform: an assessment of the science and the art. Washington, D.C.: 
Resources for the Future, 1997: Discussion Paper 97-19: 1–60. 
Kretschmer. 1996. Cost Assessment: Discussion with European Commission Secretary-General 
David Williamson 5 November 1996. (Bates number(s): 800102620-800102621). 
Source: BAT. URL: http://legacy.library.ucsf.edu/tid/xhf14a99 (accessed 02 Aug 2008). 
Krieger, Nancy et al., 2003. “Assessing health impact assessment: multidisciplinary and 
international perspectives.” Journal of Epidemiology & Community Health, 57: 659–62. 
Kübler, Daniel. 1998. Ideas as Catalytic Elements for Policy Change: Advocacy Coalitions and 
Drug Policy in Switzerland. In Public Policy and Political Ideas, edited by Dietmar Braun 
and Andreas Busch, 116-35. Cheltenham: Edward Elgar Publishing Ltd. 
Kübler, Daniel. 2001. “Understanding Policy Change with the Advocacy-Coalition Framework: 
An Application to Swiss Drug Policy.” Journal of European Public Policy, 8(4):623-41. 
Lahusen, Christian. 2002. “Commercial Consultancies in the European Union: the shape and 
structure of professional interest intermediation.” Journal of European Public Policy, 
9(5): 695-714. 
LeGresley, Eric. 1999. Understanding the Tobacco Industry: A ‘‘Vector Analysis’’ of the 
Tobacco Epidemic. Bulletin Medicus Mundi 72. 
Löfstedt, Ragnar E. 2002. The Precautionary Principle: risk, regulation and politics - 
Introductory Paper. Paper presented at a conference at Merton College, Oxford, 5-11 
April 2002. URL: http://www.21stcenturytrust.org/precprin.html. 
Löfstedt, Ragnar E. 2004. “The Swing of the Regulatory Pendulum in Europe: From 
Precautionary Principle to (Regulatory) Impact Analysis.” The Journal of Risk and 
Uncertainty, 28(3): 237-60. 
In press: Journal of Health Politics, Policy and Law 
  
34 
Löfstedt, Ragnar E. 2006) The 'Plateau-ing' of the European Better Regulation Agenda: An 
analysis of activities carried out by the Barroso Commission. London: King's Centre for 
Risk Management, King's College London. 
Mackenbach, Johan P. et al. 2013. “Health in Europe 1: The unequal health of Europeans: 
successes and failures of policies.” The Lancet Europe Series (online): 
http://dx.doi.org/10.1016/S0140-6736(12)62082-0. 
MacKenzie-Reid, Duncan. 1995. Memo from Duncan MacKenzie-Reid to Keith Gretton 
enclosing paper on risk assessment. (Bates number(s): 800147230-800147236). 
Source: BAT. URL: http://bat.library.ucsf.edu//tid/ctt72a99 (accessed 12 Jul 2008). 
Majone, Giandomenico. 2003. Risk Regulation in the European Union: Between Enlargement 
and Internationalization. European University Institute: Florence, Italy. 
Marcq, Fiona. 1996. Next Meeting of the Working Group on "Cost Assessment" - 12 December 
1996. (Bates number(s): 800102618). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/whf14a99 (accessed 15 Aug 2008). 
Martuzzi, Marco and Bertollini, Roberto. 2005. “The Precautionary Principle, Science and 
Human Health Protection.” Human and Ecological Risk Assessment 11(1): 63-8. 
McCarthy, Mark, et al. 2002. “A health impact assessment model for environmental changes 
attributable to development projects.” Journal of Epidemiology and Community 
Health, 56(8), 611-6. 
Meads, Richard. 2007. European Risk Forum Policy Brief 01 - Regulatory Impact Analysis. 
Brussels: 
http://www.euportal2.be/images/erf%20policy%20brief%20ria%20004%20rm%20fina
l%20draft.pdf (accessed 1st April 2009): European Risk Forum. 
Michaelson, Jay. 1996. “Rethinking regulatory reform: toxics, politics, and ethics.” Yale Law 
Journal, 105: 1891–925. 
Miller, Charles. 1999. Fair Regulation Campaign - Formation of Campaign Group. (Bates 
number(s): 321332619-321332621). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/yuy23a99 (accessed 28 Jul 2008). 
Miller, Donald and Patassini, Domenico. (Eds.) 2005. Beyond benefit cost analysis: accounting 
for non-market values in planning evaluation. Aldershot: Ashgate Publishing Ltd. 
Mindell Jenny, et al. 2004. Enhancing the evidence base for health impact assessment. Journal 
of Epidemiology and Community Health, 58(7): 546-51. 
Mindell, Jenny and Joffe, Michael. 2003. “Health impact assessment in relation to other forms 
of impact assessment.” Journal of Public Health, 25(2): 107-12. 
Muggli, Monique E. et al. 2004. “The Tobacco Industry’s Political Efforts to Derail the EPA 
Report on ETS.” American Journal of Preventative Medicine 26(2): 167-77. 
National Cancer Institute. 1993. Respiratory Health Effects of Passive Smoking: Lung Cancer 
and Other Disorders. Smoking and Tobacco Control Monograph No. 4. (Vol. NIH 
Publication No. 93-3605). Bethesda, MD: U.S. Department of Health and Human 
Services, Public Health Service, National Institutes of Health, National Cancer Institute. 
O'Connell, Emer and Hurley, Fintan. 1997. “A review of the strengths and weaknesses of 
quantitative methods used in health impact assessment.” Public Health 123: 306–10. 
Ong, Elisa K. and Glantz, Stanton A. 2001. “Constructing 'sound science': tobacco lawyers, and 
public relations firms.” American Journal of Public Health 91(11): 1749-57. 
In press: Journal of Health Politics, Policy and Law 
  
35 
Oreskes, Naomi and Conway, Eric. 2012. Merchants of Doubt: How a Handful of Scientists 
Obscured the Truth on Issues from Tobacco Smoke to Global Warming. London: 
Bloomsbury. 
Parry, Jayne M. and Kemm, John R. (on behalf of all participants of the Evaluation of Health 
Impact Assessment workshop). 2005. “Criteria for use in the evaluation of health 
impact assessments.” Public Health, 119(12): 1122-9. 
Radaelli, Claudio M. 2005. “Diffusion without Convergence: How Political Context Shapes the 
Adoption of Regulatory Impact Assessment.” Journal of European Public Policy 12(5): 
924-43. 
Radaelli, Claudio M. 2007a. “Towards Better Research on Better Regulation.” Advanced 
Colloquium on Better Regulation (15-17 January 2007). Centre for Regulatory 
Governance, University of Exeter. 
Radaelli, Claudio M. 2007b. “Whither Better Regulation for the Lisbon Agenda?” Journal of 
European Public Policy 14(2): 190-207. 
Radaelli, Claudio M. 2008. “Evidence-Based Policy and Political Control: What does Regulatory 
Impact Assessment tell us?”  European Consortium for Political Research; 11-16 April 
2008; University of Rennes, France. 
Radaelli, Claudio.M., & Meuwese, A.C.M. 2010. “Hard Questions, Hard Solutions: 
Proceduralisation through Impact Assessment in the EU.” West European Politics, 
33(1): 136-53. 
Radaelli, Claudio M., & Meuwese, A.C.M. 2008. Better Regulation in the European Union - The 
political economy of impact assessment. Exeter. Online at: 
http://centres.exeter.ac.uk/ceg/research/riacp/documents/The%20Political%20Econo
my%20of%20Impact%20Assessment.pdf (accessed 06 Apr 2009): Centre for European 
Governance, University of Exeter. 
Renda, Andrea. 2006. Impact Assessment in the EU: The State of the Art and the Art of the 
State. Brussels: Centre for European Policy Studies. 
Royal College of Physicians. 1962. Smoking and Health: Summary of a Report of The Royal 
College of Physicians of London on Smoking in relation to Cancer of the Lung and Other 
Diseases. London: Pitman Medical Publishing. 
Sabatier, Paul A. and Jenkins-Smith, Hank C. 1999. The Advocacy Coalition Framework: An 
Assessment. In Theories of the Policy Process, edited by Paul A. Sabatier, 117-66. 
Westview Press: Oxford. 
Salay, Rebecca. and Lincoln, Paul. 2008. “Health impact assessments in the European Union.” 
The Lancet, 372(9641): 860-1. 
Sanders, Ted. 1997. Comments On: Scientific Affairs Plan for Asia 960000 970000. Philip 
Morris: 2059734366/4369. URL: http://legacy.library.ucsf.edu/tid/rer22d00  
Sen, Amartya. 2000. “The Discipline of Cost-Benefit Analysis.” The Journal of Legal Studies, 
29(2): 931-52. 
Sherrington, Philippa. 2000. Shaping the Policy Agenda: Think Tank Activity in the European 
Union. Global Society, 14(2): 173-89. 
Smith, Adrian. 2000. Policy Networks and Advocacy Coalitions: Explaining Policy Change and 
Stability in UK Industrial Pollution Policy. Environment and Planning C: Government 
and Policy, 18: 95-114. 
In press: Journal of Health Politics, Policy and Law 
  
36 
Smith, Katherine E. 2013a. “Understanding the Influence of Evidence in Public Health Policy: 
What can we learn from the 'tobacco wars'?” Social Policy & Administration, 47(4): 
382–398. 
Smith, Katherine E. 2013b. Beyond Evidence Based Policy in Public Health: The Interplay of 
Ideas.  Basingstoke: Palgrave Macmillan. 
Smith, Katherine. E. et al. 2010. “Is the increasing policy use of Impact Assessment in Europe 
likely to undermine efforts to achieve healthy public policy?” Journal of Epidemiology 
and Community Health, 64(6): 478-87.  
Smokefree Partnership. 2010a. The origin of EU Better Regulation - The Disturbing Truth. 
Brussels: the Smokefree Partnership. URL: 
http://www.smokefreepartnership.eu/IMG/pdf/Report_version_27012010_-2.pdf.  
Smokefree Partnership. 2010b. Smokefree Partnership sponsored European Parliament 
meeting entitled ‘EU Better Regulation: from economic to citizen-centric’, Brussels, 
February 2010. 
Ståhl, Timo P. 2010. “Is health recognized in the EU's policy process? An analysis of the 
European Commission's impact assessments.” The European Journal of Public Health, 
20(2):176-81. 
Summers, Martin. 2000a. Fair Regulation Campaign - Useful for EU Regulation and Regulatory 
Best Practice Discussions (Bates number(s): 322239554-322239555). Source: BAT. URL: 
http://bat.library.ucsf.edu//tid/ari23a99 (accessed 09 Jul 2008). 
Summers, Martin. 2000b. RE: Fair Regulation Campaign - Useful for EU Regulation and Best 
Practice Discussions. (Bates number(s): 322239551-322239553). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/zqi23a99 (accessed 29 Jul 2008). 
Sunstein, Cass R. 2002. The cost-benefit state - the future of regulatory protection. Chicago: 
American Bar Association. 
Tennøy, Aud et al. 2006. Uncertainty in environmental impact assessment predictions: the 
need for better communication and more transparency. Impact Assessment Project 
Appraisal, 24: 45–56. 
Turner, J. Adair. 1998. Better Regulation. (Bates number(s): 321309799-321309800). Source: 
BAT. URL: http://bat.library.ucsf.edu//tid/epk23a99 (accessed 29 May 2008). 
UNICE. 1996a. Attendance List: Meeting of the "Cost Assessment" Task Force on 12 December 
1996 (Bates number(s): 800102580). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/phf14a99 (accessed 19 Aug 2008). 
UNICE. 1996b. Unice Contribution to the Intergovernmental Conference. (Bates number(s): 
321425056-321425070). Source: BAT. URL: 
http://legacy.library.ucsf.edu/tid/kza92a99 (accessed 02 Aug 2008). 
van Apeldoorn, Bastiaan. 2003. “The Struggle Over European Order: Transnational Class 
Agency in the Making of "Embedded Neoliberalism".” In State/Space - A Reader, 
edited by Neil Brenner, Bob Jessop, Martin Jones and Gordon.MacLeod. Oxford: 
Blackwell, 147-64. 
Veljanovski, Cento. 1996. European Cost-Benefit Protocol. (Bates number(s): 700514129-
700514135). Source: BAT. URL: http://legacy.library.ucsf.edu/tid/fij23a99  (accessed 
01 Aug 2008). 
Watson, Rory. 2012. “New EU tobacco legislation is delayed after health commissioner resigns 
amid claims of knowledge of bribery attempt.” BMJ News, 345:e7155. 
In press: Journal of Health Politics, Policy and Law 
  
37 
WHO. 2003. Framework Convention on Tobacco Control. URL: 
http://www.who.int/tobacco/framework/WHO_FCTC_english.pdf 
WHO. 2008. Tobacco Industry Interference with Tobacco Control. World Health Organization. 
URL: http://www.who.int/tobacco/resources/publications/9789241597340.pdf 
(accessed 26 May 2010). 
Wilkinson, David et al. 2004. Sustainable Development in the European Commission's 
Integrated Impact Assessments for 2003. London: Institute for European 
Environmental Policy. 
Woll, Cornelia. 2007. “Leading the Dance? Power and Political Resources of Business 
Lobbyists.” Journal of Public Policy, 27(1): 57-78. 
Woods, Mervyn. 1995. Preliminary UNICE Contribution to Preparation of the 1996 Inter-
Governmental Conference (IGC) (Bates number(s): 600523390-600523398). Source: 
BAT. URL: http://legacy.library.ucsf.edu/tid/bbj28a99 (accessed 24 Jul 2008). 
Wright, John et al. 2005. “Institutionalizing policy-level health impact assessment in Europe: is 
coupling health impact assessment with strategic environmental assessment the next 
step forward?” Bulletin of the World Health Organization, 83(6): 472-7. 
 
 
